Document:

Exhibit 10(f)  

Summary of Viacom Inc. Compensation for Outside Directors  

Cash Compensation  

	•
	Outside
directors receive an annual retainer of $60,000, payable in equal installments quarterly in advance, plus a per meeting attendance fee of $2,000;

	•
	The
Chairs of the Audit, Compensation, Strategic Planning and Ad Hoc Committees each receive an annual retainer of $20,000, payable in equal installments quarterly in
advance, and the members of those committees receive a per meeting attendance fee of $2,000; and

	•
	The
Chair of the Nominating and Governance Committee receives an annual retainer of $15,000, payable in equal installments quarterly in advance, and the members of that
committee receive a per meeting attendance fee of $1,500. 

        Outside
directors may elect to defer their cash compensation under the Viacom Inc. Deferred Compensation Plan for Non-Employee Directors, or any successor plan. 

Equity Compensation  

        Outside directors receive the following: 

	•
	an
initial grant of 10,000 stock options to purchase shares of Class B common stock on the date the director joins the Board, which options vest one year from the
date of grant; and

	•
	an
annual grant of 4,000 stock options to purchase shares of Class B common stock on January 31 of each year, which options vest in equal installments over a
period of three years. 

        The
exercise price of the stock options is the closing price of Viacom's Class B common stock on the New York Stock Exchange (NYSE) (or such other exchange on which the
Class B common stock may then be listed) on the date of grant. 

        Effective
as of the Company's 2005 annual meeting, subject to stockholder approval, the Viacom Inc. 2000 Stock Option Plan for Outside Directors will be amended (and renamed the
Viacom Inc. Equity Plan for Outside Directors) to provide that outside directors will automatically receive, in addition to the cash and equity compensation described above, the following
compensation: 

	•
	an
initial grant of restricted share units (RSUs) on the date stockholder approval of the amended plan is received equal to $55,000 in value based on the closing price of
the Class B Common Stock on the NYSE (or such other exchange on which the Class B common stock may then be listed) on the date of grant, which RSUs vest one year from the date of grant;
and

	•
	an
annual grant of RSUs on January 31st of each year equal to $55,000 in value based on the closing price of the Class B Common Stock on the NYSE (or such
other exchange on which the Class B common stock may then be listed) on the date of grant, which RSUs vest one year from the date of grant. 

        RSUs
are payable to outside directors in shares of Class B Common Stock upon vesting unless the outside director elects to defer settlement of the RSUs to a future date. Outside
directors are entitled
to receive dividend equivalents on the RSUs in the event the Company pays a regular cash dividend on its Class B Common Stock. Dividend equivalents shall accrue on the RSUs (including deferred
RSUs) in accordance with the plan until the RSUs are settled, at which time they are payable in shares of Class B Common Stock. The Viacom Inc. Equity Plan for Outside Directors will be
contained in an annex to Viacom's 2005 proxy statement.QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.52  

 
 

Amendment No. 1    
    

        This AMENDMENT No. 1 (the "Amendment") is entered into as of the 21 day of December, 2004 ("the Effective Date") by and among EYETECH
PHARMACEUTICALS, INC., a Delaware Corporation having its principal place of business at 3 Times Square, 12th Floor, New York, NY 10036 ("EYETECH") and ISIS
PHARMACEUTICALS, INC., a Delaware Corporation having its principal place of business at 2292 Faraday Ave., Carlsbad CA ("ISIS") to amend the License Agreement effective as of
December 31, 2001 ("the Agreement"), by and among EYETECH and ISIS. Capitalized terms used and not otherwise defined herein shall have the meanings given them in the Agreement. 

        WHEREAS,
ISIS wishes to induce Eyetech to agree to provide a Consent of Assignment by agreeing to amend the Agreement to amend the definition of Net Sales and timing of milestone
payments set forth therein. 

        Now,
therefore in consideration of the foregoing and the covenants and promises contained in this Amendment, the Parties hereby amend the Agreement as follows: 

        1.     The
preamble of Section 3.1.2 is hereby amended as follows: 

        3.1.2    Milestones.    EYETECH will pay the following milestones to ISIS within 30 days after achieving such
milestones: 

        2.     The
definition for Net Sales set forth in Exhibit A is hereby replaced with the following definition: 

        "Net Sales"    means the gross amounts billed or invoiced by Eyetech, its affiliates and sublicensees for EYE001 worldwide, less
the following deductions: 

        (a)   trade,
quantity and cash discounts allowed, but expressly excluding discounts or allowances offered as part of a package of products that includes EYE001 sold by
Eyetech, its affiliates or sublicensees; 

        (b)   refunds,
chargebacks and any other allowances which effectively reduce the net selling price; 

        (c)   actual
product returns, credits and allowances allowed to customers, and actual bad debts; 

        (d)   rebates
actually paid or credited to any governmental agency (or branch thereof) or to any third party payor, administrator or contractee; 

        (e)   discounts
mandated by, or granted to meet the requirements of, applicable state, provincial or federal law, wholesaler, including required chargebacks and retroactive
price reductions; 

        (f)    transportation,
freight, postage charges and other charges, such as insurance, relating thereto, in each case included as a specific line item on an invoice to such
third parties; and 

        (g)   taxes,
excises or other governmental charges upon or measured by the production, sale, transportation, delivery or use of goods, in each case included as a specific line
item on an invoice to such third parties. 

        If
any such sales to third parties are made in transactions that are not at arm's length between the buyer and the seller, then the gross amount to be included in the calculation of Net
Sales shall be the amount that would have been invoiced had the transaction been conducted at arm's length. Such amount that would have been invoiced shall be determined, wherever possible, by
reference to the average selling price of EYE001 in arm's-length transactions in the relevant country. 

1

 

        If
Eyetech, its affiliate or sublicensee sells EYE001 in unfinished form to a third party for resale, then the gross amount to be included in the calculation of Net Sales arising from
such sale shall be the amount invoiced by the third party upon resale, in lieu of the amounts invoiced by Eyetech, its affiliates or sublicensee when selling EYE001 in unfinished form. Otherwise,
where Eyetech, its affiliate or sublicensee sells EYE001 in finished form to a third party that does not require a sublicense under the Eyetech Patent Rights for further resale (each such third party
hereinafter a "Distributor"), the amount to be included in the calculation of Net Sales shall be the price invoiced from Eyetech or its affiliate or
sublicensee to the third party, not the amount invoiced by the third party upon resale. 

        If,
in addition to or in lieu of a transfer price paid for quantities of EYE001 supplied, any Distributor provides consideration to Eyetech, its affiliate or sublicensee in connection
with any EYE001 or the Distributor's rights or relationship with Eyetech, its affiliate or sublicensee in relation thereto, then such consideration shall be included in the calculation of Net Sales in
the Quarter in which it becomes due to Eyetech or its affiliate or sublicensee (as applicable). Notwithstanding the foregoing, amounts received by Eyetech, or its affiliates or sublicensees, for the
sale of EYE001 among Eyetech and its affiliates or sublicensees for resale shall not be included in the computation of Net Sales hereunder. 

        With
the exception of clinical trials, including Phase IV trials, and the use of reasonable samples, EyeTech, its affiliates or sublicensees will be treated as having sold EYE001 for an
amount equal to the fair market value of EYE001 if: (a) EYE001 is used by EyeTech, its affiliates or sublicensees without charge or provision of invoice, or (b) EYE001 is provided to a
third party by EyeTech, its affiliates or sublicensees without charge or provision of invoice and used by such third party. 

        Net
Sales shall be determined from books and records maintained in accordance with GAAP, consistently applied throughout the organization and across all products of the entity whose
sales of EYE001 are giving rise to Net Sales. 

        3.     Except
as specified above, all other terms and provisions of the Agreement shall remain in full force and effect. 

        4.     This
Amendment shall be construed and the rights of the parties determined in accordance with the laws of the law of the state of Delaware without giving effect to its
conflict of laws rules. 

        5.     This
Amendment may be executed in counterparts, each of which shall constitute an original but both of which shall together constitute one and the same instrument. 

* * * *  

        IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the Effective Date. 

	EYETECH PHARMACEUTICALS, INC.	 	ISIS PHARMACEUTICALS, INC.
	

By:	

/s/  GLENN SBLENDORIO      
 Name: Glenn Sblendorio

Title: Chief Financial Officer	
 	

By:	

/s/  B. LYNNE PARSHALL      
 Name: B. Lynne Parshall

Title: EVP & CFO

2

QuickLinks

Amendment No. 1QuickLinks
 -- Click here to rapidly navigate through this document

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24 

Exhibit 10.53  

 
 

AGREEMENT FOR SALE
  
    AND
  
    ASSIGNMENT OF RIGHTS    
    

        THIS AGREEMENT (the "Agreement") is made and entered into as of this 21 day of December, 2004 (the
"Effective Date") by and between ISIS PHARMACEUTICALS, INC., a subsisting corporation under the
laws of the State of Delaware ("ISIS") and DRUG ROYALTY USA, INC., a subsisting corporation under
the laws of the State of Nevada ("DRC"). 

RECITALS:  

	A.
	Capitalized terms used herein have the meanings set forth in Schedule "A" hereto.

	B.
	ISIS is the exclusive owner of the Licensed Patent Rights and has granted to Eyetech, pursuant to the License Agreement, a
non-exclusive license under the Licensed Patent Rights, including a right of sublicense, to make, have made, use and sell the Product world-wide.

	C.
	ISIS and DRC have entered into a non-binding letter of intent dated [***], 2004 (the
"LOI"), pursuant to which ISIS has agreed to sell, assign, transfer, set-over and convey to DRC the Assigned Rights in consideration of the
payment by DRC to ISIS of the Purchase Price. DRC and ISIS wish to enter into this Agreement to effect the sale, assignment, transfer, set-over and conveyance to DRC of the Assigned Rights
on the terms and conditions set forth herein. 

        NOW, THEREFORE, in consideration of the recitals and mutual covenants set forth herein, the payment by DRC to ISIS of
[***] US dollars (US$[***]) and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged), the parties agree
as follows: 

 
 

ARTICLE 1
  ASSIGNMENT AND SALE    
    

1.1    Sale and Assignment.    Subject to the terms and conditions of this Agreement, ISIS hereby sells, assigns, transfers,
sets-over and conveys to DRC all right, title and interest in and to the Assigned Rights free and clear of any Encumbrance. For greater certainty, DRC shall not purchase or assume any of
ISIS' obligations under the License Agreement in connection with the foregoing, including any responsibility to prosecute and/or maintain the Patents or the Licensed Patent Rights. 

        An
example as to how royalty payments would be calculated and payable to DRC in connection with the Royalty Interest and to ISIS in connection with the ISIS Royalty Interest is set out
in Schedule "B" hereto. 

1.2    Purchase Price.

	(a)
	In
full consideration of the sale, assignment, transfer, set-over and conveyance of the Assigned Rights, DRC shall pay to ISIS an aggregate purchase price (the
"Purchase Price") of up to twenty-four million US dollars (US$24,000,000), as follows:

	(i)
	[***]
million US dollars (US$[***]) due and payable on [***], 2005 (the "First Payment
Date");

	(ii)
	[***]
million US dollars (US$[***]) due and payable on [***], 2006 ("Second Payment
Date"); and 

 

	(iii)
	[***]
million US dollars (US$[***]) due and payable on [***], 2007 ("Third Payment
Date").

	(b)
	Notwithstanding
any other term of this Agreement, the payment by DRC of each component of the Purchase Price contemplated by Subsection 1.2(a) shall be conditional upon: (i) no
Level II Event of Default having occurred (except to the extent that any such Level II Event of Default also constitutes a Special Event of Default and such Special Event of Default has been waived by
DRC in writing); (ii) no Special Event of Default having occurred and not been waived by DRC in writing; and (iii) DRC having received, not more than [***] days
prior to the date for payment of such component, a certificate of the Executive Vice President of ISIS certifying, after due inquiry, that no Level II Event of Default has occurred and that no Special
Event of Default has occurred. ISIS acknowledges that DRC shall rely on such certificate in paying the applicable component of the Purchase Price. In addition, notwithstanding any other term of this
Agreement, if DRC's obligation to pay any component of the Purchase Price (as it comes due on either the First Payment Date, Second Payment Date or Third Payment Date) occurs after an Eyetech Breach
Date, any such payment obligation will be stayed as long as a Cure Period remains in effect and continues. Once the applicable Cure Period ends and all of the conditions set forth in subparts
(i) through (iii) of this subsection 1.2(b) have been met, such component of the Purchase price will become due and payable.

	(c)
	In
addition to the certificate contemplated by Subsection 1.2(b), when each component of the Purchase Price becomes due, ISIS shall provide to DRC: (i) a written update of the
representations and warranties set out in Section 2.1, including an updated list of the Patents current as of the date of the certificate contemplated by Subsection 1.2(b) or if there has been
no change in the Patents as of such date, written confirmation that there has been no such change, as well as ISIS' performance of and compliance with its covenants under Article 3 and
(ii) a written confirmation that no Level I Event of Default on the part of ISIS has occurred, or if such a Level I Event of Default has occurred, a description thereof and the actions ISIS is
taking to remedy same. Without limiting any other rights or remedies of DRC hereunder, including pursuant to Section 5.3, Article 6 and Section 7.2, DRC may not withhold payment
of any component of the Purchase Price based on such updated representations, warranties and covenants unless a Level II Event of Default has occurred and, to the extent that such Level II Event of
Default also constitutes a Special Event of Default, DRC has not waived in writing such Special Event of Default.

	(d)
	Subject
to Subsections 1.2(b), 5.A.2(b), 5.A.2(c) and 5.3, the Purchase Price is not subject to adjustment and shall be payable when due regardless of the value at any time of the
Royalty Interest. Notwithstanding the foregoing, DRC may, in its sole discretion, pay to ISIS any component(s) of the Purchase Price in advance at any time.

	(e)
	The
Purchase Price shall be paid by wire transfer of federal funds or other immediately available funds to one or more bank accounts designated in writing by ISIS. If any of the
payment dates under Subsection 1.2(a) is not a business day, the payment shall be made on the next following business day. 

1.3    Eyetech Consent.    On or before Closing, ISIS shall obtain from Eyetech, in writing, a consent and agreement (the
"Eyetech Consent") in form and substance reasonably satisfactory to DRC, providing, among other matters: (i) Eyetech's consent to the sale,
assignment, transfer, set-over and conveyance by ISIS to DRC of the Assigned Rights and acknowledgement that DRC shall have the right to exercise such Assigned Rights directly against
Eyetech; (ii) Eyetech's agreement to pay the Royalties to [***] (without any setoff against any amounts owing by ISIS to Eyetech) in accordance with the terms and
conditions of the License Agreement, as amended in accordance with the terms of this Agreement; 

2

 

(iii) Eyetech's
agreement to provide directly to both DRC and ISIS copies of any royalty statements and other information that Eyetech is obligated to provide under the License Agreement in
connection with the Royalties; (iv) Eyetech's agreement that ISIS may disclose to DRC information provided to ISIS by Eyetech pursuant to or in connection with the License Agreement; and
(v) Eyetech's agreement to permit an independent, certified public accountant appointed by DRC, in ISIS' stead, to examine Eyetech's records and other material documents relating or relevant to
the calculation of the Royalties or to the Net Sales of the Product associated therewith; and (vi) Eyetech's confirmation that DRC shall have the right to assign all right, title and interest
in and to the Assigned Rights and the Eyetech Consent to a [***], at any time, without further notice to or consent from Eyetech. In connection with the foregoing, ISIS shall
use its commercially reasonable efforts to obtain from Eyetech on or before Closing, in writing, in form and substance reasonably satisfactory to DRC, Eyetech's agreement to change the Reporting
Periods under the License Agreement to calendar quarters. 

1.4    Entitlement and Payments; No Offsets.

	(a)
	Notwithstanding
(i) any claim, counterclaim or setoff which ISIS may have against DRC or which any third party may have against ISIS, (ii) the sale, assignment,
transfer, set-over and conveyance of the Assigned Rights by ISIS to DRC in accordance with the terms hereof and (iii) Eyetech's consent and agreement to make payments directly to
[***] pursuant to the Eyetech Consent, if ISIS receives any payment which constitutes part of the Royalty Interest, or if DRC receives any payment which constitutes part of the
ISIS Royalty Interest, the receiving party shall (I) hold same in trust for the other party; (II) remit such payment to the other party within two (2) business days of discovery
of same by the receiving party; and (III) remit such amount to the other party without any withholding or deduction therefrom.

	(b)
	In
the event that, notwithstanding the terms of the Eyetech Consent, Eyetech offsets all or part of the Royalty Interest against any right, payment or claim of Eyetech against ISIS
(whether or not made pursuant to the License Agreement), ISIS shall pay to DRC, within [***] days of Eyetech exercising such offset, an amount equal to (i) the Royalty
Interest payable to DRC if no amount was offset less (ii) the amount of Royalty Interest actually received by DRC as a result of such offset. Provided ISIS makes the payment to DRC contemplated
in the preceding sentence, ISIS shall be entitled to retain any amount subsequently recovered from Eyetech in respect of such offset.

	(c)
	ISIS
shall not hereinafter enter into any agreement with Eyetech unless such agreement contains an express prohibition against offset by Eyetech of any overpayment to or amount due
from ISIS under such agreement against the Royalty Interest or any part thereof. 

 
 

ARTICLE 2
  REPRESENTATIONS AND WARRANTIES    
    

        2.1    ISIS' Representations and Warranties.    Except as qualified by the exceptions set forth in Schedule "C" hereto
(the "Schedule of Exceptions"), ISIS represents and warrants to DRC as follows and acknowledges that DRC is relying on such representations and
warranties in entering into this Agreement: 

	(a)
	Recital.    Recital B is a statement of fact and is true and accurate.

	(b)
	Organization.    ISIS is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Delaware.

	(c)
	Ownership.    ISIS is the exclusive owner of all legal and equitable title to the Patents and the Assigned Rights, in each
case, free and clear of all Encumbrances. The Assigned Rights are, and shall be transferred to DRC, free and clear of any and all Encumbrances of any kind whatsoever. 

3

 

	(d)
	Authorization.    ISIS has all necessary power, right and authority to carry on its business as it is presently carried on by
ISIS, to enter into, execute and deliver this Agreement and the ISIS Closing Documents, to sell and assign the Assigned Rights to DRC and to perform all of the obligations to be performed by ISIS
hereunder and under the ISIS Closing Documents. This Agreement has been and, at Closing, each of the ISIS Closing Documents will be, duly executed and delivered by ISIS and constitute ISIS' valid and
binding obligation, enforceable against ISIS in accordance with its terms, subject to bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and to
equitable principles.

	(e)
	No Conflicts.    Neither the execution and delivery of this Agreement or the ISIS Closing Documents nor the performance or
consummation of the transactions contemplated hereby or thereby will: (i) conflict with, result in a breach or violation of, constitute a default under or accelerate the performance under the
terms of (A) to the best of ISIS' knowledge, any applicable law, any rule or regulation of any government or any agency of any government, or any judgement, order, writ, decree, permit or
license of any court or any government or any agency of any government to which ISIS may be subject, (B) any Material Agreement, including the Silicon Valley Bank Agreement and the Note
Agreements, or (C) ISIS' certificate of incorporation or by-laws; (ii) result in the creation or imposition of any Encumbrance on the Patents, the License Agreement or the
Assigned Rights, except as contemplated by Section 3.6 in favour of DRC; or (iii) relieve either party to the License Agreement of any of its obligations or enable it to terminate or
suspend its obligations thereunder.

	(f)
	License Agreement.    The License Agreement is valid, binding and enforceable in accordance with its terms and is in full
force and effect, subject to bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and to equitable principles. Neither ISIS nor, to ISIS' knowledge,
Eyetech is in default of any of its respective obligations under the License Agreement. ISIS has not waived any rights or defaults under the License Agreement and to ISIS' knowledge no event has
occurred which, after the giving of notice or the lapse of time or both, would constitute a default or breach by ISIS under the License Agreement or, to ISIS' knowledge, would constitute a default or
breach by Eyetech. A true and correct copy of the License Agreement, including all amendments thereto, is attached as Schedule "D" hereto. ISIS has not received any notice in writing that the License
Agreement has been or will be terminated or that ISIS is in default of its obligations under the License Agreement. ISIS has no intention of terminating the License Agreement and is not aware of any
events, circumstances or grounds upon which the License Agreement may be terminated by either party for breach.

	(g)
	Patents.    Schedule "E" hereto sets forth a complete list of all patent applications and registered patents which, to the
best of ISIS' knowledge, comprise the Licensed Patent Rights as of the Effective Date [***]. ISIS is the exclusive owner of the entire right, title, and interest in and to the
Patents, including the exclusive right to sue and recover for past and future infringement thereof in the Field, free and clear of any Encumbrances. All assignments evidencing ISIS' exclusive
ownership of the Patents have been duly and timely filed and recorded with the U.S. Patent and Trademark Office and such other foreign offices where such recordation is required in order to fully
protect ISIS' ownership rights to the Patents, and to ISIS' knowledge no third party has claimed or recorded any such rights with respect to any of the Patents. To ISIS' knowledge, all necessary
registration, maintenance or annuity, and renewal fees in connection with the Patents have been timely made. No government funding or university or college resources or facilities were used in the
development of any of the inventions disclosed in the Patents in a manner that would give such government or university or college any ownership interest in or license to the Patents. There are no
royalties, fees or 

4

 

other
payments payable by ISIS to any third party by reason of the ownership, license (or sublicense) or use of any of the Patents. To the best of ISIS' knowledge, each of the Patents and each claim
therein is valid and enforceable according to its terms. The inventions claimed in the Patents were made by employees of ISIS acting in the course of their employment. The Patents and the inventions
claimed in them have not been dedicated to the public. To the best of ISIS' knowledge, all material prior art to each of the Patents has been disclosed to or considered by the respective patent
offices during prosecution of such Patents. ISIS has not filed any disclaimer or made or permitted any other voluntary reduction in the scope of the Patents. To ISIS' knowledge, no allowable or
allowed subject matter of the Patents is subject to any competing conception claims of allowable or allowed subject matter of any patent applications or patents of any third party and have not been
the subject of any opposition proceedings, nor is ISIS aware of any basis for any such interference or opposition proceedings. ISIS has no knowledge of any infringement of the Patents by any person.
ISIS has not received any demand or claim in writing by any person that any of the Patents are, or may be invalid or that the Product infringes upon or may infringe upon or otherwise interferes with
any patent or other right of any kind of any third party. Other than pursuant to the License Agreement, ISIS has not granted any person the right under the Patents to make, use or sell the Product or
any other product that would infringe the Patents in the Field. ISIS has disclosed to DRC in writing all (i) licenses of all the [***] Patents and (ii) Naked
Manufacturing Licenses, in each case granted by ISIS (other than the License Agreement) and hereby confirms that each such license would constitute a Permitted License pursuant to the terms hereof. 

	(h)
	Litigation.    There is no (i) action, suit, claim, proceeding or investigation pending or threatened in writing
against ISIS, at law or in equity, (ii) arbitration proceeding to which ISIS is a party, or (iii) governmental inquiry pending or threatened in writing against ISIS, which, if adversely
determined, would question the validity or enforceability of the Patents, the License Agreement or the Assigned Rights or prevent the consummation of the transactions contemplated by this Agreement or
otherwise adversely affect the Assigned Rights. There is no action or suit by ISIS pending or threatened in writing against others relating to the Patents, the License Agreement, the Assigned Rights
or the Product. None of the Patents are subject to any outstanding decree, order, judgment, or stipulation restricting in any manner the use or licensing thereof by ISIS or, to Isis' knowledge,
Eyetech.

	(i)
	No Consent.    Other than the Eyetech Consent and the Silicon Valley Bank Consent, no consent, approval, license, order,
authorization, registration, declaration or filing with or of any person is required by ISIS in connection with the execution and delivery by ISIS of this Agreement and the ISIS Closing Documents, the
performance by ISIS of its obligations under this Agreement and the ISIS Closing Documents or the consummation of any of the transactions contemplated hereby or thereby.

	(j)
	Other Agreements.    Other than the License Agreement, ISIS has not entered into any contract, agreement, commitment or
undertaking creating an Encumbrance relating to or affecting the Assigned Rights.

	(k)
	Disclosure.    Except as qualified by the Schedule of Exceptions, no representation or warranty made by ISIS in this
Agreement contains any untrue statement of a material fact or omits to state any material fact necessary to make any such representation or warranty not misleading to a prospective buyer of the
Assigned Rights seeking full information as to the Patents, the Licensed Patent Rights, the License Agreement, the Assigned Rights and the Product.

	(l)
	Residency.    During the five (5) year period preceding the Effective Date, ISIS has maintained its chief executive
office in the State of California. 

5

 

	(m)
	Good Faith and Purpose.    As of the Effective Date, ISIS is entering this Agreement with no contemplation of insolvency and
with no intent to hinder, delay or defraud any of ISIS' present or future creditors. The purpose of the transaction set out in this agreement is to enable ISIS to acquire the Purchase Price.

	(n)
	Bankruptcy.    No corporate action has been taken or is pending, no other steps (including any steps under Title 11 of the
United States Code, as amended) have been taken and no legal proceedings have been commenced or are, to the knowledge of ISIS, threatened in writing or pending for (A) the
winding-up, liquidation, dissolution, administration or reorganization of ISIS, (B) ISIS to enter into any composition or arrangement with its creditors, or (C) the
appointment of a receiver, administrative receiver, trustee or similar officer in respect of ISIS or any of its property, undertakings or assets.

	(o)
	Solvency.    ISIS is solvent and able to pay its debts as they fall due and has not suspended or threatened to suspend making
payments (whether principal or interest) with respect to all or any class of its debts in consequence of this Agreement for the sale, assignment, transfer, set-over and conveyance of the
Assigned Rights or any other obligation or transaction contemplated in this Agreement.

	(p)
	Silicon Valley Bank Agreement.    The Silicon Valley Bank Agreement is valid, binding and enforceable in accordance with its
terms and is in full force and effect, subject to bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and to equitable principles. Neither ISIS nor, to
ISIS' knowledge, Silicon Valley Bank is in default of any of its respective obligations under the Silicon Valley Bank Agreement. ISIS has not waived any rights or defaults under the Silicon Valley
Bank Agreement and to ISIS' knowledge no event has occurred which, after the giving of notice or the lapse of time or both, would constitute a default or breach by ISIS under the Silicon Valley Bank
Agreement or, to ISIS' knowledge, would constitute a default or breach by Silicon Valley Bank. A true and correct copy of the Silicon Valley Bank Agreement, including all amendments thereto, has been
provided to DRC. ISIS has not received any notice in writing pursuant to the Silicon Valley Bank Agreement that such agreement has been or will be terminated or that ISIS is in default of its
obligations under the Silicon Valley Bank Agreement. ISIS has no intention of terminating the Silicon Valley Bank Agreement and is not aware of any events, circumstances or grounds upon which the
Silicon Valley Bank Agreement may be terminated by either party for breach. The amount of the Loan outstanding as at [***], 2004 is approximately
$[***].

	(q)
	Note Agreements.    Each of the Note Agreements is valid, binding and enforceable in accordance with its terms and is in full
force and effect, subject to bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and to equitable principles. Neither ISIS nor, to ISIS' knowledge, any
other person is in default of any of its respective obligations under the Note Agreements. ISIS has not waived any rights or defaults under the Note Agreements and to ISIS' knowledge no event has
occurred which, after the giving of notice or the lapse of time or both, would constitute a default or breach by ISIS under the Note Agreements or, to ISIS' knowledge, would constitute a default or
breach by any other person. True and correct copies of the Note Agreements, including all amendments thereto, have been provided to DRC. ISIS has not received any notice in writing pursuant to the
Note Agreements that any such agreements have been or will be terminated or that ISIS is in default of its obligations under any such agreements. ISIS has no intention of terminating the Note
Agreements and is not aware of any events, circumstances or grounds upon which the Note Agreements may be terminated for breach. 

6

 

2.2    DRC's Representations and Warranties.    DRC represents and warrants to ISIS as follows and acknowledges that ISIS is relying
on such representations and warranties in entering into this Agreement: 

	(a)
	Organization.    DRC is a corporation duly incorporated, validly existing and in good standing under the laws of the State of
Nevada.

	(b)
	Authorization.    DRC has all necessary power, right and authority to carry on its business as it is presently carried on by
DRC, to enter into, execute and deliver this Agreement and the DRC Closing Documents, and to perform all of the obligations to be performed by DRC hereunder and thereunder. This Agreement has been
and, at Closing, each of the DRC Closing Documents will be, duly executed and delivered by DRC and constitute DRC's valid and binding obligation, enforceable against DRC in accordance with its terms,
subject to bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and to equitable principles.

	(c)
	No Conflict.    Neither the execution and delivery of this Agreement or the DRC Closing Documents nor the performance or
consummation of the transactions contemplated hereby or thereby will conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by the terms
of (i) to the best of DRC's knowledge, any applicable law, any rule or regulation of any government or any agency of any government, or any judgment, order, writ, decree, permit or license of
any court or government or any agency of any government to which DRC may be subject; (ii) any contract, agreement, commitment or instrument to which DRC is a party or by which DRC or any of its
assets is bound or committed; or (iii) DRC's constituent charter documents or other governing instruments.

	(d)
	No Consent.    No consent, approval, license, order or authorization, registration, declaration or filing with or of any
person is required by DRC in connection with the execution and delivery by DRC of this Agreement and the DRC Closing Documents, the performance by it of its obligations under this Agreement and the
DRC Closing Documents or the consummation of any of the transactions contemplated hereby or thereby. 

2.3    Knowledge.    Any reference in Sections 2.1 or 2.2 to "ISIS' knowledge", "DRC's knowledge" or any similar expressions shall
mean the knowledge of any executive officer of ISIS or DRC or any attorney advising such party with respect to this Agreement, the Patents or the License Agreement, as applicable. 

2.4    Survival of Representations and Warranties.    All representations and warranties of the parties hereunder shall survive the
execution and delivery of this Agreement and Closing without time limit. Any investigation or other examination that may have been made or may be made at any time by or on behalf of the party to whom
representations and warranties are made shall not limit, diminish or in any way affect the representations and warranties in this Agreement, and each party may rely on the representations and
warranties in this Agreement irrespective of any information obtained by it by any investigation, examination or otherwise unless such party has actual knowledge as at the Effective Date that such
representations or warranties are false or incorrect. 

 
 

ARTICLE 3
  COVENANTS    
    

3.1    Notification.

	(a)
	ISIS
shall promptly notify DRC in writing of any Event of Default, Special Event of Default or any default or termination by Eyetech under the License Agreement or the commencement of
any litigation, opposition, request for reexamination or similar proceeding in respect of the 

7

 

Patents,
the License Agreement, the Assigned Rights or the Product and each such notification shall contain full particulars of the event described therein. ISIS shall keep DRC reasonably informed as
to the status of any such default, litigation, opposition, request for reexamination or proceeding. Notwithstanding the foregoing, subject to Sections 3.5 and 7.1 and DRC's rights under the Security
Agreement, ISIS will at all times control such default, litigation, opposition, request for reexamination or proceeding. 

	(b)
	Promptly
after receipt by ISIS of any material written notice, certificate, offer, proposal, correspondence or other written communication (each, a
"Communication") relating directly to the Patents, the License Agreement, the Assigned Rights or the Product, in each case for use within the Field,
ISIS shall inform DRC of the receipt and substance of such Communication and if in writing shall furnish DRC with a copy of such Communication.

	(c)
	ISIS
shall promptly notify DRC in writing of any Permitted License (i) of the [***] Patents, or (ii) that constitutes a Naked Manufacturing
License, in each case hereinafter granted after the Effective Date by ISIS. For each such notice Isis will include the name of the licensee, the nature of the license, the Patents and/or Licensed
Patent Rights licensed and the field of use.

	(d)
	ISIS
shall promptly notify DRC in writing of any change in the Patents from the list set forth in Schedule "E" as updated from time to time pursuant to this Subsection 3.1(d) or
Subsection 1.2(c).

	(e)
	Following
receipt by ISIS of a notice from DRC that DRC intends to enforce its rights under the Security Agreement (in accordance with the provisions thereof and of this Agreement),
ISIS shall promptly provide DRC a written list of each and every Permitted License under the [***] Patents as at the date of such notice. 

3.2    Certain Conduct.    Without the prior written consent of DRC, ISIS shall not: (i) sell, assign, transfer, deliver,
license or otherwise dispose of any of the Patents for use in the Field; (ii) create or permit to exist any Encumbrance (other than the Encumbrance created in favor of DRC under the Security
Agreement) on the Patents, the License Agreement or the Assigned Rights; (iii) respond to any Communication that could adversely affect the exploitation of the Patents or the Product in the
Field; (iv) amend or terminate the License Agreement or fail to perform and fulfill its obligations under the License Agreement in accordance with the terms thereof, except as permitted under
Section 9.9 of the License Agreement; (v) consent to any assignment of the License Agreement by Eyetech; or (vi) agree to do any of the foregoing or take any other action that
does or would materially reduce or otherwise materially adversely affect the Patents in the Field, the License Agreement or the Assigned Rights or cause any representation or warranty set forth in
Section 2.1 to become untrue as of the date of such action, including (A) granting or permitting any license of the Patents, other than under the License Agreement, for use in the Field,
(B) failing to diligently process, prosecute, and maintain in full force and effect the [***] Patents in each of the countries of the Major Market in which ISIS has an
issued patent or pending patent application or (C) failing to diligently enforce in full force and effect the [***] Patents in the Field in each of the countries of the
Major Market in which ISIS has an issued patent. For purposes of clarification, the granting of a Permitted License will not be deemed a violation of this Section 3.2. 

3.3    Termination of License Agreement.    In the event that the License Agreement is terminated by ISIS with the prior written
consent of DRC or by Eyetech, ISIS covenants to use its commercially reasonable efforts to (a) negotiate, execute and deliver (i) a new license agreement for the license of the Licensed
Patent Rights for use in the Field, (ii) if both parties agree, in good faith, that the negotiation, execution and delivery of such a new license agreement is highly unlikely, an assignment or
sale of the Licensed Patent Rights for use in the Field, or (iii) any other arrangement for the exploitation of the Licensed Patent Rights for use in the Field, each on terms that are
reasonably satisfactory to DRC, and (b) obtain all approvals and consents which are necessary or, in DRC's sole 

8

 

discretion,
desirable in connection therewith, including a written consent of the other party to the New License Agreement substantially in the form of the Eyetech Consent. If ISIS does not complete
such negotiation, execution and delivery and obtain such approvals and consents within [***] months following the termination of the License Agreement, then ISIS shall assist
and cooperate with DRC, and DRC shall be authorized in the name of ISIS for the benefit of DRC, at DRC's sole discretion, cost and expense (including DRC's payment of ISIS' reasonable attorney fees in
connection therewith, if any), to negotiate, execute and deliver a new license agreement for the license of the Licensed Patent Rights for use in the Field on the same or better terms (when taken as a
whole) as the License Agreement. For avoidance of doubt, as between the parties hereto, the Royalty Interest shall be equal to (i) [***]% of all payments, property and
other consideration that is less than or equal to [***] for any calendar years prior to 2010 plus the pro rated dollar amount attributable to any Additional Period,
(ii) [***]% of all payments, property and other consideration that is greater than [***] but less than or equal to [***]
for any calendar years prior to 2010 plus the pro rated dollar amount attributable to any Additional Period and (iii) [***]% of all payments, property and other
consideration that is greater than [***] for any calendar years prior to 2010 plus the pro rated dollar amount attributable to any Additional Period (collectively, the
"New Royalty Interest") under such new license, assignment or sale, or other arrangement (the "New License
Agreement"). In such event, ISIS agrees to comply with the provisions of this Agreement in connection with the New License Agreement and references herein to Royalty Interest,
the License Agreement, the Assigned Rights and the ISIS Rights shall be deemed to be references to the New Royalty Payments, the New License Agreement, all of the right, title and interest (but none
of the obligations) of ISIS in and to the New License Agreement, and subject to ISIS' right to retain rights equivalent to the ISIS Rights, respectively, and references to Eyetech shall be deemed to
be references to the other party to the New License Agreement. 

3.4    Confidentiality.    All information furnished by DRC to ISIS or by ISIS to DRC in connection with this Agreement and the
transactions contemplated hereby, as well as the terms, conditions and provisions of this Agreement, shall be kept confidential by ISIS and DRC and shall be used by ISIS and DRC only in connection
with this Agreement and the transactions contemplated hereby, except in connection with the enforcement of rights under this Agreement and except to the extent that such information (i) is
already known by the party to whom the information is disclosed or in the public domain at the time the information is disclosed, (ii) thereafter becomes lawfully obtainable from other sources,
(iii) is required to be disclosed in any document to be filed with any federal, state, provincial, municipal or other governmental department, commission, board, bureau, agency or
instrumentality, domestic or foreign, or (iv) is required to be disclosed under securities laws or regulations applicable to ISIS, DRC or their respective affiliates, or by court or
administrative order. Notwithstanding the foregoing, ISIS and DRC may disclose such information to their respective affiliates, directors, officers, investors,
bankers, advisors, trustees and representatives (collectively "Representatives"), provided that such persons shall be informed of the confidential
nature of such information and shall be obligated to keep such information confidential pursuant to the terms of this Section 3.4. 

3.5    Performance of Obligations.

	(a)
	ISIS
shall, in a timely manner and at its own expense, diligently, (i) prosecute and maintain in full force and effect each pending [***] Patent
application in each of the countries of the Major Market and, to the extent requested by DRC, the Secondary Market; (ii) maintain and keep in full force and effect any issued
[***] Patents in each of the countries of the Major Market and, to the extent requested by DRC, the Secondary Market in which ISIS has an issued [***]
Patent or pending [***] Patent application. Without limiting the foregoing, ISIS will diligently pursue, in a timely manner, the US Application and the EU Application. DRC will
reimburse ISIS for [***]% of ISIS' external costs of any such prosecution and maintenance in the Secondary Market (to the extent that DRC has requested that ISIS perform such
prosecution and maintenance). 

9

 

	(b)
	Without
limiting Subsection 3.5(a) above, ISIS promptly will advise DRC in writing of the action it intends to take to exercise, enforce or defend or of its decision not to exercise,
enforce or defend any of its rights under the Patents (to the extent that they relate to the Field) at least [***] days prior to exercising, enforcing or defending any right of
ISIS under the Patents (or failing to take any such action) to the extent that they relate to the Field and ISIS' obligations under this Agreement and at least [***] days prior
to the Exercise Date.

	(c)
	ISIS
will have the first right, but not the obligation, to enforce and defend at ISIS' expense the Patents or Licensed Patent Rights. If ISIS decides not to or otherwise fails to
diligently exercise, enforce or defend the Patents (to the extent that they relate to the Field) or perform its obligations under Subsection 3.5(a) above or the License Agreement diligently, in a
timely manner (and in any event, in respect of the prosecution and maintenance or the exercise, enforcement or defense of the Patents or Licensed Patent Rights, no less than
[***] days prior to the Exercise Date; and in respect of the performance of any other obligations of ISIS under the License Agreement, no more than
[***] months after the date on which ISIS is required to perform such obligations) and in compliance with the License Agreement, DRC will be entitled (but shall have no
obligation) to exercise, enforce or defend any such rights or perform any such obligations in the name of ISIS pursuant to the power of attorney granted under Section 7.1;  provided, however, that
(i) DRC will not admit the invalidity or unenforceability of any Licensed Patent, grant any license to the Licensed
Patents or enter into any settlement agreement without ISIS' prior written consent, such consent not to be unreasonably withheld or unduly delayed and (ii) ISIS will be able to participate in
such enforcement and defense at its own expense and with counsel of its choice provided that DRC controls such enforcement and defense. In either circumstance, ISIS shall cooperate and assist DRC in
its exercise, enforcement or defense of such rights or performance of such obligations including by making available to DRC those employees of ISIS whose assistance, testimony or presence is
reasonably required by DRC and by providing to DRC all files, books, records and other information in its possession or control related to the Patents, the Licensed Patent Rights, the License
Agreement and any other agreements requested by DRC from time to time. 

3.6    Grant of Security Interest.    As general and continuing security for the due payment and performance of all of ISIS'
obligations under this Agreement, the License Agreement and the ISIS Closing Documents, ISIS shall grant to DRC a first-ranking security interest in and to the Patents and the License Agreement (as it
relates to the ISIS Rights but not the Assigned Rights) subject to the terms of a security agreement in form and substance satisfactory to both parties (the "Security
Agreement"). The Security Agreement shall provide that, among other matters, subject to the terms and conditions hereof and thereof, (a) ISIS may exploit (including
through granting Permitted Licenses) the Patents and the Licensed Patent Rights for any purpose other than in the Field and (b) DRC may only exercise its rights under the Security Agreement to
the extent of its Damages and only as contemplated by part (ii) of Section 5.3(b) and Section 5.3(c), but not for breach of any
other provision of this Agreement by ISIS. ISIS shall keep the Patents and the License Agreement free at all times from any Encumbrances, except the
Encumbrance granted in favour of DRC or others pursuant to the terms and conditions of the Security Agreement. 

3.7    No Liability.    DRC will have no liability to ISIS for any act, omission or failure to act by DRC on behalf of ISIS under
Sections 3.3, 3.5 or 7.1 or for any act, omission or failure to act by DRC or any agent in connection with the Encumbrance granted to DRC under the Security Agreement, including in any enforcement or
realization of such Encumbrance except for any loss or damage suffered by ISIS that results from the willful misconduct or gross negligence of DRC or any such agent. No such act, omission or failure
to act by DRC or its agents shall relieve ISIS of any of its obligations hereunder or under the License Agreement. 

10

 

3.8    Books and Records.    ISIS will treat its sale and assignment to DRC of the Assigned Rights pursuant to Section 1.1 as
a sale and assignment on ISIS' books and records. Subject to any re-conveyance of the Assigned Rights under Section 5.3 or Subsections 5.A.2(b) or (c), ISIS will disclose in the
footnotes to its audited financial statements filed with the SEC that ISIS has (i) sold and assigned the Assigned Rights to DRC (or its permitted assigns) and (ii) granted DRC (or its
permitted assigns) a security interest pursuant to the Security Agreement as general and continuing security for the due payment and performance of all of ISIS' obligations under this Agreement, the
License Agreement and the ISIS Closing Documents. 

3.9    Silicon Valley Bank Loan; Notes.

	(a)
	ISIS
shall not, without the prior written consent of DRC:

	(i)
	refinance
the Loan, except to a lender dealing at arm's length with ISIS and on financial terms and conditions that (i) include a covenant by ISIS that is the same as the
financial covenant set out in section 6.8 of the Loan Agreement; and (ii) are substantially similar to the terms and conditions of the Silicon Valley Bank Agreement; or

	(ii)
	amend
the Silicon Valley Bank Agreement to increase the amount of the Loan or remove or reduce ISIS' positive or negative covenants or financial obligations thereunder; or

	(iii)
	pre-pay
the Loan in part or in full (except in connection with refinancing the Loan in accordance with Subsection 3.9(a)(i) above or as permitted under Subsection
3.9(b) below) (each, a "Repayment"); or

	(iv)
	pre-pay
or repay the Notes in full if such pre-payment or repayment of the Notes would constitute a default or an event of default under the Silicon Valley
Bank Agreement or, if applicable, the Liquidity Covenant or the Selected SVB Covenants (as each term is defined below).

	(b)
	Notwithstanding
the foregoing ISIS may make a Repayment, provided following any such Repayment and until the expiration of the Special Events of Default: (x) ISIS shall have
and maintain, as of the last day of each [***], Liquidity of at least the greater of (I) Cash Burn for such [***] multiplied by
[***] or (II) the then applicable Liquidated Damages Amount multiplied by [***] (determined as if a Special Event of Default has occurred at the
time of such Repayment and adjusted to take into account payments of the Purchase Price by DRC and Royalties received by DRC thereafter) (the "Liquidity
Covenant"); (y) the covenants of ISIS in favor of Silicon Valley Bank under Sections 7.1 and 7.4 of the Silicon Valley Bank Agreement (the
"Selected SVB Covenants") shall be deemed to be incorporated herein by reference and form a part of this Agreement with all references therein to
Silicon Valley Bank changed to DRC (and all other applicable changes as the context requires); and (z) the Special Events of Default shall be deemed to include a breach of the Selected SVB
Covenants or of the Liquidity Covenant. "Liquidity" is unrestricted cash on hand (and cash equivalents). "Cash
Burn" is the change in Liquidity from that as of the prior [***] end to Liquidity calculated at such [***] end, excluding such
extraordinary items as ISIS may reasonably request and as DRC may approve in its reasonable discretion. 

 
 

ARTICLE 4
  CLOSING; DELIVERIES ON CLOSING    
    

4.1    Closing.    Subject to satisfaction or waiver of all deliveries set forth below, the closing with respect to the sale,
assignment, transfer, set-over and conveyance of the Assigned Rights (the "Closing") shall occur on the Effective Date. 

11

 

4.2    Deliveries by ISIS.    ISIS hereby agrees to deliver to DRC on the Effective Date: 

	(a)
	A
Certificate of Good Standing from the Delaware Secretary of State dated not earlier than five (5) days prior to the date of this Agreement.

	(b)
	A
certificate signed by an authorized signing authority of ISIS certifying that the execution, delivery and performance by ISIS of this Agreement and the ISIS Closing Documents have
been duly and validly authorized by the Board of Directors of ISIS and attaching complete and accurate copies of its Certificate of Incorporation, bylaws and authorizing resolutions relating to this
Agreement.

	(c)
	An
opinion of counsel to ISIS, in a form reasonably acceptable to DRC, that: (i) the execution and delivery of this Agreement and the ISIS Closing Documents and the performance
of ISIS' obligations under this Agreement and the ISIS Closing Documents have been duly authorized; (ii) ISIS is validly existing as a corporation in good standing under the laws of the State
of Delaware and has the power and authority to execute and deliver this Agreement and the ISIS Closing Documents and perform its obligations hereunder and thereunder, that the execution, delivery and
performance of ISIS' obligations by ISIS will not contravene its charter documents, any Material Agreement, any orders of any court or tribunal or any applicable law; and (iii) this Agreement
and the ISIS Closing Documents are valid and binding on and enforceable against ISIS in accordance with their terms, subject to the usual qualifications and the creation and perfection of DRC's
Encumbrance in the Patents, the Licensed Patent Rights and the License Agreement (as it relates to the ISIS Rights but not as it relates to the Assigned Rights).

	(d)
	The
Eyetech Consent, the Security Agreement and [***] (collectively, the "ISIS Closing Documents"), a consent
by Silicon Valley Bank, in writing, in form and substance reasonably satisfactory to DRC: (i) consenting to the execution, delivery and performance of this Agreement and the Security Agreement;
(ii) releasing the negative pledge covering the Patents and the Licensed Patent Rights; (iii) releasing Silicon Valley Bank's security interest in the Patents, the Licensed Patent Rights
and the License Agreement; (iv) waiving the negative covenant in respect of [***] with respect to ISIS' obligations to DRC hereunder; (iv) confirming that the
Loan is in good standing and that the execution, delivery and performance by ISIS of this Agreement and the ISIS Closing Documents will not constitute an Event of Default and (v) agreeing to
notify DRC of the occurrence of any event of default under the Silicon Valley Bank Agreement in a reasonably timely manner (the "Silicon Valley Bank
Consent").

	(e)
	Such
other certificates, documents and financing statements as DRC may reasonably request, including a UCC financing statement satisfactory to DRC (i) to create, evidence and
perfect the first ranking Encumbrance in the Patents, the Licensed Patent Rights and the License Agreement (as it relates to the ISIS Rights but not as it relates to the Assigned Rights) created under
the Security Agreement and (ii) pursuant to the provisions of Section 7.7 hereof. 

4.3    Deliveries by DRC.    DRC hereby agrees to deliver to ISIS on the Effective Date: 

	(a)
	a
Good Standing Certificate from the Nevada Secretary of State;

	(b)
	the
Security Agreement, the Eyetech Consent and [***] (collectively, the "DRC Closing Documents");

	(c)
	a
check in the amount of [***] US dollars ($[***]); and

	(d)
	a
certificate signed by an authorized signing authority of DRC certifying that the execution, delivery and performance by DRC of this Agreement and the DRC Closing Documents have 

12

 

been
duly and validly authorized by the Board of Directors of DRC and attaching complete and accurate copies of its Articles of Incorporation, bylaws and authorizing resolutions relating to this
Agreement. 

 
 

ARTICLE 5.A
  SPECIAL EVENTS OF DEFAULT    
    

5.A.1    Special Events of Default.    Following the occurrence of any Special Event of Default, DRC shall have a period of
[***] days (such [***] days commencing on the earlier of (i) the date of receipt by DRC of written notification from ISIS of the occurrence of
such Special Event of Default and (ii) the date DRC becomes actually aware of the occurrence of a Special Event of Default and has notified ISIS of same in writing) to notify ISIS in writing
that either: (a) DRC waives such Special Event of Default, such that the parties' respective rights and obligations hereunder shall continue; or (b) DRC elects to exercise DRC's remedies
under Subsection 5.A.2 below (collectively, the "Special Event of Default Remedies"). 

5.A.2    Special Event of Default Remedies.    If DRC elects to exercise the Special Event of Default Remedies or fails to waive in
writing the Special Event of Default before the expiry of the [***] day period in Section 5.A.1, then: 

	(a)
	No [***] or
[***]: if neither the [***] nor the [***], ISIS shall be required to pay to DRC,
as liquidated damages, an amount equal to: (i) the total of all Purchase Price payments made by DRC to ISIS up to the date of the Special Event of Default (the "Default
Date"; such amount being, the "Aggregate Payments"); less (ii) the total of any Royalties received by DRC as of such
Default Date (the "Aggregate Receipts"); plus (iii) the amount required in order for DRC to have received an internal rate of return, as of the
Default Date, of [***] per cent ([***]%) per annum, compounded quarterly, on the Aggregate Payments less the Aggregate Receipts taking into account the
dates on which any such amounts were actually paid or received (collectively, the "Liquidated Damages Amount"). Upon receipt by DRC of the Liquidated
Damages Amount: (i) DRC shall re-convey to ISIS all of DRC's right, title and interest in and to the Assigned Rights; (ii) DRC shall direct Eyetech to pay all future
Royalties for Net Sales of the Product directly to ISIS; (iii) this Agreement shall terminate; and (iv) DRC shall release its security interest under the Security Agreement. In addition,
if the Default Date occurs before DRC pays any component of the Purchase Price, DRC will, subject to DRC's right (notwithstanding any other provision hereof) to retain any or all of such amounts to
off-set any Damages, repay to ISIS any Royalty Interest received by DRC under this Agreement. For greater certainty, DRC shall have no obligation to pay any components of the Purchase
Price otherwise due and payable on or after the Default Date;

	(b)
	No [***]: if the [***] but the
[***], ISIS shall be required to pay to DRC, as liquidated damages, an amount equal to the Liquidated Damages Amount reduced by the US Percentage. Upon receipt by DRC of such
amount: (i) the amount of the Purchase Price outstanding as of the Default Date, if any, shall be reduced by the US Percentage; and (ii) DRC shall re-convey to ISIS all of
DRC's right, title and interest in and to the Assigned Rights to the extent that the Assigned Rights relate to Net Sales of the Product in the EU; or

	(c)
	No [***]: if the [***] but the
[***], ISIS shall be required to pay to DRC, as liquidated damages, an amount equal to the Liquidated Damages Amount reduced by the EU Percentage. Upon receipt by DRC of such
amount: (i) the amount of the Purchase Price outstanding as of the Default Date, if any, shall be reduced by the EU Percentage; and (ii) DRC shall re-convey to ISIS all of
DRC's right, title and interest in and to the Assigned Rights to the extent that the Assigned Rights relate to Net Sales of the Product in the United States. 

13

 

	(d)
	The
parties acknowledge and agree that the Special Event of Default Remedies constitute a genuine and reasonable good faith pre-estimate of the damages that will be
suffered by DRC upon the occurrence of any Special Event of Default and shall not be characterized as or deemed to be a penalty. Notwithstanding anything to the contrary contained herein, DRC shall
not enforce its security interest in the Collateral (as such term is defined in the Security Agreement) if DRC has received payment of the Liquidated Damages Amount, as same may be reduced pursuant to
Subsections 5.A.2(b) or (c) hereof, as applicable. 

5.A.3    Payment Date and Interest on Overdue Amounts.    All amounts payable by ISIS under Section 5.A.2 shall be due within
[***] days following written notice by DRC of its election to exercise the Special Event of Default Remedies or upon the expiry of the [***] day period
in Section 5.A.1 if no written notice of waiver is provided by DRC. Overdue amounts shall bear interest at the rate of [***] per annum, compounded quarterly, until paid
in full. 

14

  

 
 

ARTICLE 5
  TERM AND TERMINATION    
    

5.1    Term.    Subject to this Article 5 and Article 5.A, the term of this Agreement shall commence as of the
Effective Date and shall continue until the date of receipt by DRC of the Royalties for the calendar quarter ending on December 31, 2009; provided that, notwithstanding the term of this
Agreement, DRC shall be entitled to receive any payments relating to the Royalty Interest accruing on or prior to the termination or expiry of this Agreement. 

5.2    [Intentionally Deleted]  

5.3    Termination on Event of Default

	(a)
	If
DRC commits a Level I Event of Default, then, on the expiry of the applicable remedy period (if any), ISIS, in addition to any other rights and remedies available hereunder, under
applicable law or in equity, may elect to terminate this Agreement by written notice to DRC, whereupon this Agreement shall terminate and DRC shall re-convey to ISIS all right, title and
interest in and to the Assigned Rights. If ISIS terminates this Agreement under this Subsection 5.3(a) before DRC pays any component of the Purchase Price (by way of Damages or otherwise), DRC shall
repay to ISIS any Royalty Interest received by DRC under this Agreement, subject to DRC's right (notwithstanding any other provision hereof) to retain any or all of such amounts to off-set
any Damages.

	(b)
	If
ISIS commits a Level I Event of Default, then, on the expiry of the applicable remedy period (if any), DRC may, subject to Section 5.4,  either (i) elect to terminate this Agreement by written
notice to ISIS, whereupon this Agreement shall terminate and DRC shall
re-convey to ISIS all right, title and interest in and to the Assigned Rights or (ii) pursue its other rights and remedies available hereunder, under applicable law or in equity,
including enforcing its security interest in the Collateral to the extent of its Damages (under and as such terms are defined in the Security Agreement).

	(c)
	If
ISIS commits a Level II Event of Default, DRC may, subject to Section 5.4, in addition to any other rights and remedies available hereunder, under applicable law or in
equity, elect to terminate this Agreement by notice in writing given to ISIS (the "Termination Event"), whereupon this Agreement shall terminate;  provided
that Section 7.7 and any provision hereof required to give effect to Section 7.7 shall survive such termination. If DRC
terminates this Agreement pursuant to this Subsection 5.3(c) then (i) DRC shall thereafter have no further obligation to pay any outstanding component of the Purchase Price; (ii) DRC
may, subject to Section 5.4 and provided the trigger is not item C set forth in the definition of the Level II Events of Default, in addition to any other rights and remedies available
hereunder, under applicable law or in equity, enforce its security interest in the Collateral (as such term is defined in the Security Agreement) to the extent of its Damages; and (iii) DRC
shall re-convey to ISIS the Assigned Rights, except that DRC shall retain a portion of the Assigned Rights calculated as follows:

	(i)
	If
the Termination Event occurs before DRC exercises any Special Event of Default Remedies, then the portion of the Assigned Rights retained by DRC shall equal: (I) the total
amount of the Purchase Price paid to ISIS hereunder plus any amount paid by DRC as Damages as a result of its failure to pay all or part of the Purchase Price; divided by
(II) twenty-four million (24 000 000);

	(ii)
	If
the Termination Event occurs after DRC exercises any Special Event of Default Remedies under Section 5.A.2(b), then the portion of the Assigned Rights retained by DRC shall
equal: (I) the total amount of the Purchase Price paid to ISIS hereunder 

15

 

(provided
a Liquidated Damages Amount was not paid), plus any amount paid by DRC as Damages as a result of its failure to pay all or part of the Purchase Price; divided by
(II) twenty-four million (24 000 000) as reduced by the US Percentage (an example of this situation is set out in the attached Schedule F hereto); and 

	(iii)
	If
the Termination Event occurs after DRC exercises any Special Event of Default Remedies under Section 5.A.2(c), then the portion of the Assigned Rights retained by DRC
shall equal: (I) the total amount of the Purchase Price paid to ISIS hereunder (provided a Liquidated Damages Amount was not paid), plus any amount paid by DRC as Damages as a result of its
failure to pay all or part of the Purchase Price; divided by (II) twenty-four million (24 000 000) as reduced by the EU Percentage (an example of this situation is set out in the
attached Schedule F hereto).

	(d)
	Notwithstanding
Subsections 5.3(a), (b) and (c), this Agreement may not be terminated by either party (the "Terminating Party"),
and the parties' respective rights and obligations hereunder shall be preserved, until the final resolution of any dispute as to the right of the Terminating Party to terminate this Agreement. 

5.4    Scope of DRC Remedies.    DRC acknowledges and agrees that if an event constitutes both an Event of Default and a Special
Event of Default, DRC may exercise its remedies either under Section 5.3 or Article 5.A but it may not exercise its remedies under both Section 5.3 and Article 5.A. 

 
 

ARTICLE 6
  MUTUAL INDEMNITY    
    

6.1    Mutual Indemnification.    ISIS hereby indemnifies and holds DRC harmless from any Damages suffered or incurred by DRC to the
extent resulting from (i) any material breach of a representation or warranty of ISIS contained herein or in any certificate or update delivered pursuant to Subsections 1.2(b) or (c), or
(ii) the material breach by ISIS of any covenant contained in this Agreement or any ISIS Closing Documents, or (iii) any Encumbrance of the Assigned Rights or any claim with respect to
the Patents, the Licensed Patent Rights or the Product. DRC hereby indemnifies and holds ISIS harmless from any Damages suffered or incurred by ISIS to the extent resulting from (i) any
material breach of a representation or warranty of DRC contained herein, or (ii) the material breach by DRC of any covenant contained in this Agreement or any DRC Closing Documents. For greater
certainty, neither party shall indemnify the other for any Damages related to any action or inaction on the part of Eyetech. 

6.2    Third Party Claims Procedure.    The indemnified party shall give notice (the "Indemnity
Notice") to the indemnifying party specifying the particulars of any third party claim within [***] days after it receives notification of the claim;  provided, however, that
failure to give such notice within such time period shall not prejudice the rights of the indemnified party except to the extent
that the failure to give such notice materially adversely affects the ability of the indemnifying party to defend the claim or to cure the breach of the representation, warranty, covenant or
obligation giving rise to the claim. Subject to the terms of this Section 6.2, the indemnifying party shall have sole control over the defense and settlement of such claim. The indemnifying
party may not settle or compromise the claim without the prior written consent of the indemnified party unless such settlement or compromise (i) involves no payment (whether by cash, securities
or other instrument), assignment, granting of a license or admission of fault or wrongdoing by the indemnified party and (ii) the indemnified party receives a comprehensive general release of
all claims from the applicable third parties. The indemnified party shall provide to the indemnifying party, in confidence, all files, books, records and other information in its possession or control
which may be relevant to the defense of such claim. The indemnified party shall co-operate in all reasonable respects in the defense of such claim but at the expense of the indemnifying
party. If the indemnifying party fails to diligently defend such claim throughout the period 

16

 

that
such claim exists, its right to defend the claim shall terminate and the indemnified party may assume the defense of such claim at the sole expense of the indemnifying party. In such event, the
indemnified party may compromise or settle such claim, without the consent of the indemnifying party. 

6.3    Limitation on Indemnity.    Neither party may make a claim for indemnity pursuant to Section 6.1 hereof unless and
until the aggregate dollar amount of all such party's Damages exceeds $[***]. Furthermore, notwithstanding Section 6.1 of this Agreement: (a) ISIS' obligation to
indemnify DRC pursuant to the terms of this Agreement will not exceed the product of (i) [***] multiplied by (ii) the total accrued payments received by ISIS
pursuant to Section 1.2 at the time of such indemnification; and (b) DRC's obligation to indemnify ISIS pursuant to the terms of this Agreement will not exceed the product of
(i) [***] multiplied by (ii) the total amounts paid (or if not paid, due and payable) by DRC pursuant to Section 1.2 at the time of such indemnification. 

6.4    No Limitation on Special Event of Default Remedies.    Notwithstanding the foregoing, this Article 6 shall not apply
to or limit any Special Event of Default Remedies. 

 
 

ARTICLE 7
  MISCELLANEOUS    
    

7.1    Additional Documents and Acts; Powers of Attorney.

	(a)
	After
the Closing, each of the parties hereto shall execute and deliver such additional documents, certificates and instruments, and perform such additional acts, as may be reasonably
requested and necessary or appropriate to carry out all of the provisions of this Agreement and to consummate all of the transactions contemplated by this Agreement.

	(b)
	ISIS
hereby appoints DRC as its attorney-in-fact with full authority in the place and stead of ISIS and in the name of ISIS, or otherwise from time to time in
DRC's discretion, to take any action and to execute any instrument consistent with the terms of this Agreement which DRC deems necessary or advisable for the purpose of exercising any rights granted
to DRC pursuant to Section 3.3 and 3.5 hereof in the event that ISIS fails to complete its obligations or exercise its rights under such Sections within the applicable time periods set out
therein. The foregoing grant of authority is a power of attorney, coupled with an interest, and such appointment shall be irrevocable for the term hereof. ISIS hereby ratifies all that such attorney
shall lawfully do or cause to be done by virtue hereof.

	(c)
	DRC
hereby appoints ISIS as its attorney-in-fact with full authority in the place and stead of DRC and in the name of DRC, or otherwise from time to time in
ISIS' discretion, to take any action and to execute any instrument consistent with the terms of this Agreement which ISIS deems necessary or advisable for the purpose of exercising any rights granted
to ISIS pursuant to Section 5A.2 and 5.3 hereof in the event that DRC fails to complete its obligation to re-convey the applicable portion of the Assigned Rights (as determined
under such Sections) within the applicable time periods set out therein. The foregoing grant of authority is a power of attorney, coupled with an interest, and such appointment will be irrevocable for
the term hereof. DRC hereby ratifies all that such attorney will lawfully do or cause to be done by virtue hereof. 

7.2    Specific Performance.    Each of the parties hereto acknowledges that the other party may have no adequate remedy at law if
it fails to perform any of its obligations under this Agreement. In such event, each of the parties agrees that the other party shall have the right, in addition to any other rights it may have
(whether at law or in equity), to pursue equitable remedies such as injunction and specific performance of this Agreement. 

17

 

7.3    Notices.    All notices, consents, waivers and other communications hereunder shall be in writing and shall be delivered in
person, sent by overnight courier, facsimile transmission or posted by registered or certified mail, return receipt requested, with postage prepaid, addressed as follows: 

	(i)
	if
to DRC: 

Drug
Royalty USA, Inc.

101 Convention Center Drive

Suite 850

P.O. Box 50401

Las Vegas, Nevada 89109

U.S.A. 

Attention:    Behzad
Khosrowshahi

Fax No.    (702) 598-3651 

with
a copy to: 

Drug
Royalty Corporation Inc.

Suite 3102 Royal Bank Plaza

Toronto, Ontario

M5J 2J3 

Attention:    Behzad
Khosrowshahi

Fax No.    (416) 863-5161 

and
to: 

Fasken
Martineau DuMoulin LLP

Toronto Dominion Bank Tower

P.O. Box 20, Toronto-Dominion Centre

Toronto, Ontario

M5K 1N6 

Attention:    Scott
Conover

Fax No.    (416) 364-7813 

	(ii)
	if
to ISIS: 

ISIS
Pharmaceuticals, Inc.

2292 Faraday Avenue

Carlsbad, California 92008 

Attention:    B.
Lynne Parshall

                      Executive Vice President, CFO and Director

Fax No.    (760) 603-4652 

with
a copy to: 

General
Counsel

Fax
No.    (760) 268-4922 

or
to such other address or addresses as DRC or ISIS may from time to time designate by notice as provided herein. Any such notice shall be deemed given when actually received when so delivered
personally or by overnight courier or if mailed, other than during a period of general discontinuance or disruption of postal service due to strike, lockout or otherwise, on the fifth
(5th) day after its postmarked date thereof or if sent by facsimile transmission on the date sent if such day is a business 

18

 

day
or the next following business day if such day is not a business day. For the purposes of this Agreement, "business day" means any day other than
Saturday, Sunday or a statutory or civic holiday observed in Toronto, Ontario or Carlsbad, California. 

7.4    Successors and Assigns.    This Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of ISIS and DRC. This Agreement may not be assigned in whole or in part by either party without the prior written consent of the other party; provided,
however that (i) DRC may assign this Agreement in whole or in part by way of [***] and/or to [***] and/or as part of a
sale of a material part of DRC whether by way of reorganization or otherwise, without the consent of ISIS provided DRC gives prompt written notice of such assignment to ISIS and the assignee (or in
the case of any financial institution or other lender, any purchaser from such financial institution or other lender) agrees in writing to be bound hereby and (ii) ISIS may assign this
Agreement in connection with the sale of all or substantially all of its business (whether by sale of assets, stock or merger) without the consent of DRC provided ISIS gives prompt written notice of
such assignment to DRC and the assignee agrees in writing to be bound hereby. 

7.5    Expenses.    Each party shall be responsible for and bear all of its own costs and expenses (including but not limited to any
legal fees, any accountants' fees and any brokers' or finders' or investment banking fees or any prior commitment in respect thereof) with regard to the negotiation and consummation of the transaction
contemplated hereby. Notwithstanding the foregoing, each party represents and warrants to the other that the other party will not be liable for any brokerage
commission, finder's fee or other like payment in connection with the transactions contemplated hereby because of any action taken by, or agreement or understanding reached by, that party. 

7.6    Entire Agreement.    This Agreement, together with the Schedules to this Agreement and officer's certificates and other
documents to be delivered pursuant hereto (which are incorporated herein by reference), supersedes any other agreement, whether written or oral, that may have been made or entered into by the parties
hereto relating to the matters contemplated hereby, including the LOI and the letter of intent between the parties dated [***], 2004, and constitutes the entire agreement of
the parties hereto with respect to the subject matter hereof. Any conflict or inconsistency between the main body of this Agreement, the Schedules and/or any other documents to be delivered pursuant
hereto shall be resolved in accordance with the following order of priority: (a) main body of this Agreement; (b) Schedules; and (c) other documents,  except that the Schedule of
Exceptions is intended to qualify ISIS' representations and warranties under this Agreement. 

7.7    True Sale Security Agreement. 

	(a)
	ISIS
and DRC intend and agree that the sale, assignment, transfer, set-over and conveyance of the Assigned Rights hereunder be a true sale by ISIS to DRC that is absolute
and irrevocable (except as permitted and contemplated by Section 5.3 hereof) and that provides DRC with the full benefits of ownership of the Assigned Rights, and neither ISIS nor DRC intends
the transactions contemplated hereunder to be, or for any purpose to be characterized as, a loan from DRC to ISIS. ISIS waives any right to contest or otherwise assert that this Agreement is other
than a true sale by ISIS to DRC under applicable law, which waiver shall be enforceable against ISIS in any bankruptcy or insolvency proceeding relating to ISIS.

	(b)
	It
is not the intention of DRC or ISIS that the sale, assignment, transfer, set-over and conveyance of the Assigned Rights by ISIS be deemed a grant of a security interest
in the Assigned Rights by ISIS to DRC to secure a debt or other payment obligation of ISIS. However, without in any manner qualifying, derogating from, or modifying the foregoing, to the extent that,
the intention of the parties notwithstanding, any court or other tribunal having jurisdiction thereof determines that the Assigned Rights or any of the payments with respect thereto are property of
ISIS or its bankruptcy estate, in order to secure the prompt payment and performance as and when due of ISIS' obligations hereunder, ISIS hereby grants to DRC 

19

 

a
first priority security interest in and to all of ISIS' right, title and interest in, to and under the Assigned Rights and the proceeds thereof to secure (i) the rights of DRC hereunder and
(ii) a loan by DRC to ISIS in the amount of the Purchase Price plus a reasonable return for the Assigned Rights. ISIS agrees that, with respect to the Assigned Rights and the proceeds thereof,
ISIS intends that DRC will have all of the rights and remedies of a perfected first priority secured party under the Uniform Commercial Code. ISIS and DRC shall, consistent with this Agreement, take
such actions as may be necessary to help ensure that the foregoing precautionary grant of a security interest to DRC be a first priority perfected security interest in favor of DRC under applicable
law and will be maintained as such throughout the term of this Agreement. Without limiting the generality of the foregoing, ISIS agrees that it shall not, and shall not assist or encourage any third
party to, challenge or contest the validity, attachment, perfection or priority of such security interest. The foregoing precautionary grant of a security interest to DRC by ISIS is granted as of the
date of this Agreement and shall attach to the Assigned Rights as of the date of this Agreement. 

7.8    Amendments, Supplements, Waivers.    This Agreement may be amended or supplemented only by a written agreement signed by DRC
and ISIS. Any waiver of, or consent to depart from, the requirements of any provision of this Agreement shall be effective only if it is in writing and signed by the party giving it, and only in the
specific instance and for the specific purpose for which it has been given. No failure on the part of any party to exercise, and no delay in exercising, any right under this Agreement shall operate as
a waiver of such right. No single or partial exercise of any such right shall preclude any other or further exercise of such right or the exercise of any other right. 

7.9    Interpretation.    When a reference is made in this Agreement to Articles, Sections or Schedules, such reference shall be to
an Article, Section or Schedule to this Agreement unless otherwise indicated. The words "include," "includes" and "including" when used herein shall be deemed in each case to be followed by the words
"without limitation" and shall not be construed to limit any general statement which it follows to the specific or similar items or matters immediately following it. "Person" includes an individual,
body corporate, partnership, joint venture, cooperative, trust or unincorporated organization, domestic or foreign government or any agency or instrumentality thereof, or any other entity recognized
by law. Neither party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other. 

7.10    Public Announcement.    The parties agree to discuss and coordinate all public announcements concerning the transactions
contemplated herein except as may be necessary, in the opinion of counsel
to the party making such disclosure, to comply with the requirements of any applicable law. If any such public statement or release is so required, the party making such disclosure shall consult with
the other party prior to making such statement or release, and the parties shall use reasonable efforts, acting in good faith, to agree upon a text for such statement or release which is satisfactory
to all parties. The form of press release to be issued by DRC immediately after Closing with respect to this transaction shall be mutually agreed to by the parties on or prior to the Effective Date.
Notwithstanding the foregoing, nothing herein shall prohibit DRC or any of its affiliates from disclosing DRC's interest in the Assigned Rights to any of its or their affiliates, agents,
representatives and employees, in any annual or other periodic corporate report, to any financing sources (whether equity or debt) and its or their legal, financial or industry advisors, or to any
actual or potential underwriter and its legal, accounting and industry advisors, in connection with securing financing. 

7.11    Headings and Captions.    The headings and captions in this Agreement are for convenience and reference purposes only and
shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. 

7.12    Currency.    Unless specified otherwise, all statements of or references to monetary amounts in this Agreement are to US
Dollars. 

20

 

7.13    Severability.    If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall
nevertheless be given full force and effect. 

7.14    Governing Law.    This Agreement shall be governed by and construed, interpreted and enforced in accordance with the laws of
the State of New York, without giving effect to the principles of conflicts of law thereof. Subject to Section 7.15, the parties hereto attorn to and submit to the non-exclusive
jurisdiction of the courts of the State of New York. 

7.15    Binding Arbitration of Certain Disputes.

	(a)
	Any
dispute, controversy or claim directly relating to whether (i) [***], (ii) [***], (iii) the Special Event of
Default described in Subsection [***] of the definition thereof set forth in Schedule "A" hereto has occurred, (iv) the Level I Event of Default described in Subsection
[***] of the definition thereof set forth in Schedule "A" hereto has occurred, (v) the obligations under Subsection [***] or Subsection
[***] have been fulfilled and/or (vi) the obligations under Section [***] have been fulfilled (each an "Arbitrable
Matter"), shall be resolved as follows. The senior management of both parties shall meet to attempt to resolve such Arbitrable Matter. If the senior management of each party
cannot resolve such Arbitrable Matter within [***] days after either party requests such a meeting of the senior management of the parties, then at either party's option,
dispute resolution may be pursued as described in Subsection 7.15(b).

	(b)
	Except
as otherwise provided in this Agreement, any Arbitrable Matter which the parties are unable to resolve pursuant to the procedures set forth in Subsection 7.15(a) shall be
submitted to and resolved by an arbitration conducted in the English language in (i) New York, New York if initiated by ISIS and (ii) in San Diego, CA if initiated by DRC, in each case
in accordance with the rules for commercial arbitration, as then in effect, of the American Arbitration Association, subject to the terms as herein provided (including, notwithstanding the rules or
practices of the American Arbitration Association, the designation of three (3) arbitrators as provided in this Subsection 7.15(b)). Within [***] days following a demand
for arbitration submitted to the American Arbitration Association, or within such other time period as the parties may agree, ISIS and DRC shall each designate one arbitrator having substantial
professional experience with regard to drug patents, drug valuation and the interpretation of contracts similar to this Agreement who is not an employee or member or former employee or former member
of a firm or organization that the designating party regularly retains to provide legal advice ("Independent"). Within [***]
days after the appointment of the two arbitrators, the two arbitrators shall designate a third arbitrator mutually acceptable to them who has similar professional experience and is Independent of the
parties. If the arbitrator chosen by ISIS and the arbitrator chosen by DRC fail to agree upon the third arbitrator within such [***] day period, a third arbitrator with
professional experience as aforesaid and Independent of the parties shall be appointed by the American Arbitration Association as soon as practicable and in any event no later than
[***] days following receipt by the American Arbitration Association of notice of the need to appoint a third arbitrator. Disputes about arbitration procedure shall be resolved
by the arbitrators, or failing agreement, by the American Arbitration Association.

	(c)
	The
three arbitrators shall commence consideration of the dispute at issue at a mutually agreed upon time within [***] days (or such longer period as may be
acceptable to the parties) after the designation of the three arbitrators. The parties hereby agree that at any time after the designation of the three arbitrators, a majority of the arbitrators
(either on their own or as the result of a request by either party) can, if the arbitrators consider it appropriate in the circumstances of the dispute at hand, require (i) DRC to pay
components of the Purchase Price, then due or at such time as they later come due, into [***], to be held on 

21

 

terms
considered appropriate by the majority of the arbitrators, (ii) the parties to jointly instruct [***] to retain payments of the Royalty Interest in
[***], and/or (iii) if the Arbitrable Matter concerns a Special Event of Default or Liquidated Damages, require Isis to pay an assumed Liquidated Damages Amount (as
determined by the arbitrators) into [***], in each case during and until resolution of the Arbitrable Matter at hand. The arbitrators shall not have the authority to modify any
term or provision of this Agreement. The arbitrators may proceed to an award notwithstanding the failure of either party (after receiving timely and proper notice) to participate in the proceedings.
The arbitration proceeding shall be held in private, with all documents, materials, exhibits and testimony being considered and designated confidential, and shall include an opportunity for the
parties to conduct discovery in advance of the proceeding, which discovery may be limited by rules established by the arbitrators. In no event shall punitive damages be assessed against either party.
Notwithstanding the foregoing, the parties agree that they shall attempt and they intend that they and the arbitrators shall use their best efforts in that attempt, to conclude the arbitration
proceeding and have a final decision from the arbitrators within [***] days from the date the three arbitrators begin hearing the dispute; provided,
however, that the arbitrators shall be entitled to extend such [***] day period one or more times, if a majority of the arbitrators deem such extension
desirable. The arbitrators shall immediately deliver a written decision with respect to the dispute to each of the parties, who shall promptly act in accordance therewith. Each party agrees that any
decision of the arbitrators shall be final, conclusive and binding, no appeal or review shall lie therefrom. It is specifically understood and agreed that either party may enforce any award rendered
pursuant to the arbitration provisions of this Section 7.15 by bringing suit in any New York or California state or federal court of competent jurisdiction. 

	(d)
	If
any time limit set forth in this Section 7.15 is not met by either party, by the arbitrators or by the American Arbitration Association, as applicable, then either party may
on written notice to the arbitrators or the American Arbitration Association, as the case may be, and the other party submit the Arbitrable Matter to a court of competent jurisdiction for resolution
and the arbitration proceedings shall immediately terminate and the costs and expenses attributable to the arbitrators shall be borne equally by the parties.

	(e)
	Nothing
in this Section 7.15 shall prevent either party from joining the other party in any court or other legal proceeding commenced by a third party or require any dispute,
controversy or claim that is not an Arbitrable Matter to be arbitrated, consolidated, held in obeyance or suspended. For greater certainty, any dispute, controversy or claim that is not an Arbitrable
Matter may not be submitted to arbitration but may be submitted by either party to a court of competent jurisdiction for resolution. 

7.16    WAIVER OF JURY TRIAL.    EACH PARTY IRREVOCABLY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING IN
CONNECTION WITH OR RELATING TO THIS AGREEMENT OR ANY AGREEMENT ENTERED INTO PURSUANT HERETO AND AGREES THAT ANY SUCH SUIT, ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. THE
PROVISION OF THIS SECTION 7.15 SHALL NOT APPLY TO ANY ACTION TO ENFORCE THE LICENSED PATENT RIGHTS AGAINST EYETECH OR OTHERS IN THE FIELD. 

7.17    Time.    Time is of the essence of this Agreement and each of its provisions. 

        7.18    Counterparts and Facsimile Execution.    This Agreement may be executed in two or more counterparts, each of
which shall be an original, but all of which together shall constitute one and the same instrument. To evidence the fact that it has executed this Agreement, a party may send a copy of its executed
counterpart to the other party by facsimile transmission. That party shall be deemed to 

22

 

have
executed this Agreement on the date it sent such facsimile transmission. In such event, such party shall forthwith deliver to the other party the counterpart of this Agreement executed by such
party. 

        IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

	 	 	ISIS PHARMACEUTICALS, INC.
	

 	
 	

By:	

/s/  B. LYNNE PARSHALL      
 Name: B. Lynne Parshall

Title: Executive Vice President, CFO and Director
	

 	
 	
DRUG ROYALTY USA, INC.
	

 	
 	

By:	

/s/  BEHZAD KHOSROWSHAHI      
 Name: Behzad Khosrowshahi Title: President

23

  

 
 

SCHEDULE "A"
  DEFINITIONS    
    

        Capitalized terms used in this Agreement and not defined in this Schedule "A" shall have the meanings attributed thereto in the License Agreement. 

        "Additional Period" means the number of days between the date of termination of the License Agreement and the date of first commercial
sale of the Product under the New License Agreement. 

        "Aggregate Payments" has the meaning set forth in Subsection 5.A.2(a) of this Agreement. 

        "Aggregate Receipts" has the meaning set forth in Subsection 5.A.2(a) of this Agreement. 

        "Agreement" has the meaning set forth on the cover page of this Agreement. 

        "Arbitrable Matter" has the meaning set forth in Subsection 7.15(a) of this Agreement. 

        "Assigned Rights" means ISIS' entire right, title and interest in and to the following rights under the License Agreement: 

	(i)
	the
right to receive the Royalty Interest;

	(ii)
	the
right to receive royalty statements, as provided under Sections 4.1 and 8.4 of the License Agreement, in respect of Net Sales of the Product made on or before December 31,
2009;

	(iii)
	the
right to audit those records of Eyetech relating or relevant to Net Sales of the Product made on or before December 31, 2009, as provided under Sections 4.4 and 8.4 of
the License Agreement; and

	(iv)
	the
right, upon the exercise by DRC of its rights under the Security Agreement, to exploit the Patents, the Licensed Patent Rights and/or the Product in the Field. 

Notwithstanding
the foregoing, except for as specified in clauses (i) through (iv) above, ISIS retains all it right, title and interests under the License Agreement, including, but not
limited to its right to any amounts payable by Eyetech as provided under Sections 3.1.1 or 3.1.2 of the License Agreement and, subject to the terms of this Agreement and the Security Agreement, the
right to exploit (including through the granting of Permitted Licenses) the Patents, Licensed Patent Rights and/or Product outside the Field (collectively, the "ISIS
Rights"). 

        "Business Day" has the meaning set forth in Section 7.3 of this Agreement. 

        "Cash Burn" has the meaning attributed thereto in Section 3.9 of this Agreement. 

        "Closing" has the meaning set forth in Section 4.1 of this Agreement. 

        "Communication" has the meaning set forth in Subsection 3.1(b) of this Agreement. 

        [***] 

        "Cure Period" has the meaning set out in the definition of Special Events of Default. 

        "Damages" means any damage, loss, claim, cost, liability, action, cause of action, demand or expense, including reasonable legal fees,
suffered or incurred by either party in connection with this Agreement, the Security Agreement and/or the Eyetech Consent. 

        "Default Date" has the meaning set forth in Subsection 5.A.2(a) of this Agreement. 

        "DRC" has the meaning set forth on the cover page of this Agreement. 

        "DRC Closing Documents" has the meaning set forth in Subsection 4.3(b). 

        "Effective Date" has the meaning set forth on the cover page of this Agreement. 

24

 

        "Encumbrance" means any lien, charge, security interest, mortgage, option, privilege, pledge, trust or deemed trust (whether contractual,
statutory or otherwise arising) or any other encumbrance, right or claim of any other person of any kind whatsoever whether choate or inchoate, other than the Permitted Licenses. 

        "EU" means the European Union as constituted from time to time. 

        "EU Application" means a patent application filed by ISIS with the European Patent Office that if issued would meet the requirements for
an EU Patent. 

        "EU Patent" means one or more patent(s) issued in the EU, the issued claims of which [***]. 

        "EU Percentage" means (i) [***] per cent ([***]%) if the applicable Special Event
of Default occurs during the first [***] months following the first commercial sale of the Product in the US (the "US Twenty-four Month
Period"); or (ii) the percentage of worldwide Net Sales that are comprised of Net Sales of the Product in the EU for the [***] calendar months
immediately preceding the Default Date, if the Default Date occurs after the expiry of the US [***] Month Period. The percentage of worldwide Net Sales that are comprised of
Net Sales of the Product in the EU shall be determined by examining EyeTech's royalty reports delivered under the License Agreement. If such reports do not provide enough information to determine the
appropriate percentage, then the appropriate percentage shall be determined based on information of US and EU Net Sales as reported by IMS. If IMS (or a comparable company acceptable to both DRC and
ISIS, acting reasonably) is not able to provide such data, then the appropriate percentage shall be determined based on publicly available information acceptable to both DRC and ISIS acting
reasonably. 

        "EU [***]Month Period" has the meaning set forth in the definition
of US Percentage. 

        "Event of Default" means any Level I Event of Default or any Level II Event of Default. 

        "Exercise Date" means the date upon which ISIS must or does exercise any right or perform any obligation of ISIS under the Patents or
Licensed Patent Rights (to the extent that they directly or indirectly relate to the Field and ISIS' obligations under this Agreement) to comply with the License Agreement or must enforce or defend
such right to avoid the loss of such right or any adverse effect to ISIS' rights under the Patents or Licensed Patent Rights to the extent that they directly or indirectly relate to the Field and
ISIS' obligations under this Agreement. 

        "Eyetech" means Eyetech Pharmaceuticals, Inc. 

        "Eyetech Breach Date" has the meaning set out in the definition of Special Events of Default. 

        "Eyetech Consent" has the meaning set forth in Section 1.3 of this Agreement. 

        "FDA" means the United States Food and Drug Administration. 

        "Field" means [***]. 

        "First Payment Date" has the meaning set forth in clause (i) of Subsection 1.2(a) of this Agreement. 

        "Independent" has the meaning set forth in Subsection 7.15(b) of this Agreement. 

        "IMS" means IMS Health Incorporated. 

        "ISIS" has the meaning set forth on the cover page of this Agreement. 

        "ISIS Closing Documents" has the meaning set forth in Subsection 4.2(d) of this Agreement. 

        "ISIS Rights" has the meaning set forth in the definition of Assigned Rights above. 

        "ISIS Royalty Interest" means all Royalties not forming part of the Royalty Interest. 

25

 

        "Level I Events of Default".    Each of the following events will constitute a Level I Event of Default under this Agreement: 

	A.
	if DRC fails to make any payment of the Purchase Price when due and does not remedy such failure within [***]
days after receiving notice from ISIS specifying the failure;

	B.
	if ISIS, without the prior written consent of DRC:

	(i)
	materially
fails to perform and fulfill its obligations under the License Agreement in accordance with the terms thereof, except as permitted under Section 9.9 of the License
Agreement, or terminates the License Agreement; or

	(ii)
	fails
to diligently and in a timely manner continue to process, prosecute and maintain the Patents in each of the countries of the Major Market in which ISIS has an issued Patent or
pending Patent application such that they are not in full force and effect and do not contain claims which, but for the License Agreement, would be infringed by the making, using and selling of the
Product, and does not remedy such default, in the case of a default that is remediable, within [***] days after ISIS receives written notice from DRC specifying such default;

 

	C.
	if:

	(i)
	the
representations and warranties made by ISIS under Subsection 2.1(c) and the first sentence of Subsection 2.1(f) (including in the certificate(s) received by DRC pursuant to
Subsection 1.2(c)), prove to be false or incorrect; or

	(ii)
	any
other representation or warranty made by ISIS under this Agreement and any ISIS Closing Documents on the Effective Date proves to be false or incorrect in any material respect;
or

 

	D.
	if:

	(i)
	either
party does not generally pay its debts as they become due,

	(ii)
	an
authorized officer of a party admits in writing such party's inability to pay its debts generally,

	(iii)
	either
party makes an assignment for the benefit of creditors or commits an act of insolvency or bankruptcy within the meaning of applicable law;

 

	E.
	if any proceeding, voluntary or involuntary, is commenced respecting either party pursuant to any statute relating to bankruptcy,
insolvency, reorganization of debts, liquidation, winding up or dissolution; provided, however, in the case of any involuntary bankruptcy proceeding
such right to terminate will only become effective if the party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] days of the filing
thereof;

	F.
	if any receiver, manager, trustee, sequester, custodian or liquidator or person with similar powers is appointed judicially or
extrajudicially for either party or for any material portion of its property;

	G.
	if either party passes any resolution for its liquidation, winding up or dissolution or ceases to carry on business in the ordinary
course; or

	H.
	if ISIS breaches, or fails to observe or perform, any material agreement, covenant or provision in this Agreement or the ISIS Closing
Documents and does not remedy such breach or failure, in the case of a breach or failure that is remediable, within [***] days after ISIS receives written notice from DRC
specifying such breach or failure. 

26

 

For
purposes of clarification, ISIS granting a Permitted License cannot be considered a Level I Event of Default. 

        "Level II Events of Default".    Each of the following events will constitute a Level II Event of Default under this Agreement: 

	A.
	if ISIS, without the prior written consent of DRC:

	(i)
	sells,
assigns, transfers, delivers, licenses or otherwise disposes of any of the Patents for use in the Field; or

	(ii)
	creates
or permits to exist any Encumbrance (other than the Encumbrance created in favor of DRC under the Security Agreement) on the Patents, the License Agreement or the Assigned
Rights;

 

	B.
	if ISIS fails to pay the Liquidated Damages Amount or the amounts required pursuant to Subsections 5.A.2(b) or (c), as applicable, when
due; or

	C.
	if ISIS fails to meet or exceed the Minimum Liquidity or materially breaches Section 3.9 of this Agreement;  provided, however, that this subsection C shall no longer constitute a Level II Event of Default when [***]. 

For
purposes of clarification, ISIS granting a Permitted License cannot be considered a Level II Event of Default. 

        "License Agreement" means the license agreement dated as of December 31, 2001 between ISIS and Eyetech, as such agreement may be
amended, replaced, succeeded or substituted from time to time. 

        "Licensed Patent Rights" has the meaning ascribed to it in the License Agreement. 

        "Liquidated Damages Amount" has the meaning set forth in Subsection 5.A.2(a) of this Agreement. 

        "Liquidity" has the meaning attributed thereto in Section 3.9 of this Agreement. 

        "Loan" means the loan granted by Silicon Valley Bank to ISIS in the original principal amount of US$32,000,000 pursuant to the Silicon
Valley Bank Agreement. 

        [***]

        "LOI" has the meaning set forth on the cover page of this Agreement. 

        "Major Market" means the [***]. 

        [***] 

        "Material Agreement" at any time means, any contract, commitment or instrument to which ISIS is a party that is listed as an exhibit to a
periodic or current report filed by ISIS with the United States Securities and Exchange Commission at such time. 

        "Minimum Liquidity" at the time immediately prior to the First Payment Date, Second Payment Date or Third Payment Date, as applicable,
means Liquidity equal to the total of: (i) all amounts (including principal and interest) of the Loan (or any replacement thereof pursuant to Section 3.9 of this Agreement) then
outstanding; (ii) the Liquidated Damages Amount, assuming for the purposes of this definition that the Purchase Price component that is due on the immediately following payment date has been
paid by DRC; and (iii) ISIS' Cash Burn as the calculation relates to the [***] period ending immediately prior to the date of the certificate contemplated by Subsection
1.2(b). 

27

 

        "Naked Manufacturing License" means a Permitted License granted by ISIS that includes rights to one or more [***]
Patents and that is a license to enable the manufacture of products (at scales of more than [***]) outside the Field to conduct drug development (but not solely drug research)
but does not include a Permitted License to enable the manufacture of a product that is outside the Field and that is discovered, developed or commercialized under a bona fide collaboration between
ISIS and a third party. 

        "Net Sales" has the meaning set forth in the License Agreement [***], provided that if DRC re-conveys
to ISIS the Assigned Rights, or any part thereof, pursuant to Subsection 5.3(a), Subsection 5.A.2 (b) or Subsection 5.A.2 (c) of this Agreement, "Net
Sales" shall be deemed to mean the Net Sales that relate to the Assigned Rights, if any, that have been retained by DRC. 

        "New Royalty Interest" has the meaning set forth in Section 3.3 of this Agreement. 

        "New License Agreement" has the meaning set forth in Section 3.3 of this Agreement. 

        "New US Patent" means a US patent that is issued to ISIS based on the US Application, the issued claims of which
[***]. 

        "Note Agreements" means, collectively, the Notes, the indenture between ISIS and Wells Fargo Bank Minnesota, National Association, as
trustee, dated as of May 1, 2002 (the "Note Indenture") and any related documentation. 

        "Notes" means the five and one half per cent (51/2%) convertible subordinated notes of ISIS due 2009. 

        "Patents" means the patents listed on Schedule "E" hereto, as such Schedule may be updated from time to time pursuant to Subsection 1.2(c)
or Subsection 3.1(d). For avoidance of doubt, "Patents" are included in the Licensed Patent Rights. 

        "Permitted License(s)" means a license granted by ISIS to a third party to exploit the Patents outside the Field that does not grant the
licensee thereunder a security interest in the Patents. 

        "person" includes an individual, corporation, partnership, joint venture, trust, syndicate, unincorporated organization, the Crown or any
agency or instrumentality thereof or any other entity recognized by law. 

        "Product" means Eyetech's EYE001 NX1838 non-antisense therapeutic product (also known as Macugen), or any product containing
Eyetech's EYE001 NX1838 non-antisense therapeutic product for the treatment of ophthalmic conditions. The Product will also include any minor chemical modifications to EYE001 NX1838. 

        "Purchase Price" has the meaning set forth in Section 1.2 of this Agreement. 

        "Representatives" has the meaning set forth in Section 3.4 of this Agreement. 

        "Royalties" means all of the royalties payable by Eyetech in respect of Net Sales made by Eyetech, its affiliates and sublicensees made on
or before December 31, 2009 (as calculated in accordance with and as provided under Sections 3.1.3, 4.1 and 8.4 of the License Agreement) and any collections or recoveries received by ISIS or
lump sum payments made by Eyetech or its sublicensees in lieu thereof, including in connection with any litigation to enforce the License Agreement or the Licensed Patent Rights. 

        "Royalty Interest" means, in connection with Net Sales of the Product made on or before December 31, 2009: 

	(a)
	one
hundred percent (100%) of any Royalties on annual Net Sales where such Net Sales are less than or equal to five hundred million US dollars (US$500,000,000) for any calendar year; 

28

 

	(b)
	fifty
per cent (50%) of any Royalties on annual Net Sales where such Net Sales greater than five hundred million US dollars (US$500,000,000) but less than or equal to one billion US
dollars (US$1,000,000,000) for any calendar year; and

	(c)
	ten
per cent (10%) of any Royalties on annual Net Sales where such Net Sales are greater than one billion US dollars (US$1,000,000,000) for any calendar year. 

        "Schedule of Exceptions" has the meaning set forth in Section 2.1 of this Agreement. 

        "Second Payment Date" has the meaning set forth in clause (ii) of Subsection 1.2(a) of this Agreement. 

        "Secondary Market" means any country requested by DRC via written notice to ISIS to be treated as a Secondary Market country for the
purposes hereof (effective upon ISIS' receipt of such notice). 

        "Security Agreement" has the meaning set forth in Section 3.6 of this Agreement. 

        "Selected SVB Covenants" has the meaning set forth in Subsection 3.9(b) of this Agreement. 

        "Silicon Valley Bank Agreement" means the loan and security agreement between ISIS and Silicon Valley Bank dated December 15, 2003. 

        "Silicon Valley Bank Consent" has the meaning set forth in Subsection 4.2(d) of this Agreement. 

        "Special Event of Default" means the occurrence of any one of the following events prior to the earlier of December 31, 2009 and
the date on which both the [***]: 

	A.
	Eyetech fails at any time to pay to [***] any Royalties on Net Sales of the Product made in the United States or
in the EU or in both the United States and EU (an "Eyetech Breach Date") excluding any such failure that is cured by Eyetech making the required payment
within [***] days following written notice to Eyetech by DRC or ISIS of such failure (the "Cure Period");  provided, however, that if Eyetech provides ISIS
or DRC a Communication, after an Eyetech Breach Date and prior to the expiry of the applicable Cure
Period, to the effect that Eyetech [***], then the date of such Communication shall be the date of the occurrence of this Special Event of Default. For greater certainty, any
amounts determined to be payable by Eyetech as a result of an audit of Eyetech's records under the License Agreement will not be considered a failure to pay for the purposes of this Subsection
provided that Eyetech pays the Royalty so determined to [***] in accordance with the License Agreement and the Eyetech Consent;

	B.
	the License Agreement is terminated by Eyetech or by ISIS without the prior written consent of DRC;

	C.
	the validity or enforceability of [***] is challenged in an action based on 35 U.S.C. §§
100 et seq. and is subject to a final Markman decision that provides a basis for a dispositive motion on validity or enforceability such that
[***] is found to be invalid and/or unenforceable;

	D.
	the occurrence of a default or event of default under (i) the Silicon Valley Bank Agreement or any other agreement relating to
the Loan or any replacement thereof that is not cured in the period, if any, prescribed thereunder or waived in writing by Silicon Valley Bank or (ii) any of the applicable covenants set out in
Section 3.9 of this Agreement; or

	E.
	the occurrence of a default or event of default under the Note Agreements that is not cured in the period, if any, prescribed
thereunder. 

For
purposes of clarification, ISIS granting a Permitted License cannot be considered a Special Event of Default. 

        "Special Event of Default Remedies" has the meaning set forth in Section 5.A.1 of this Agreement. 

29

 

        "Terminating Party" has the meaning set forth in Subsection 5.3(c) of this Agreement. 

        "Third Payment Date" has the meaning set forth in clause (iii) of Subsection 1.2(a) of this Agreement. 

        "US Application" means a US patent application filed by ISIS claiming [***] which if issued would meet the
requirements for a New US Patent. 

        "US Percentage" means (i) [***] if the applicable Special Event of Default occurs during the first
[***] months following the first commercial sale of the Product in the EU (the "EU [***]  Month Period"); or (ii) the percentage of worldwide Net Sales
that are comprised of Net Sales of the Product in the United States for the
[***] calendar months immediately preceding the Default Date, if the Default Date occurs after the expiry of the EU [***] Month Period. The percentage
of worldwide Net Sales that are comprised of Net Sales of the Product in the United States shall be determined by examining EyeTech's royalty reports delivered under the License Agreement. If such
reports do not provide enough information to determine the appropriate percentage, then the appropriate percentage shall be determined based on information of US and EU Net Sales as reported by IMS.
If IMS (or a comparable company acceptable to both DRC and ISIS, acting reasonably) is not able to provide such data, then the appropriate percentage shall be determined based on publicly available
information acceptable to both DRC and ISIS acting reasonably. 

        "US [***] Month Period" has the meaning set forth in the
definition of EU Percentage. 

30

  

 
 

SCHEDULE "B"
  CALCULATION OF ROYALTY INTEREST AND ISIS ROYALTY INTEREST    
    

        The following sets out an example of how any amounts payable to DRC and to ISIS (if applicable) pursuant to the Royalty Interest and the ISIS Royalty Interest,
respectively, will be calculated: 

	(a)
	If
as of the expiry of the first calendar quarter of Year X Net Sales for Year X are less than or equal to five hundred million US dollars (US$500,000,000) (the
"First Threshold"), then the Royalty Interest shall equal one hundred per cent (100%) of all royalties payable for such quarter (the
"First DRC Payment"). i.e.: 

	Cumulative Net Sales as of

Expiry of First Calendar

Quarter of Year X
	 	Royalty Interest/

First DRC Payment
	 	ISIS Royalty Interest

	US$100,000,000	 	100% of all royalties payable for first calendar quarter

(i.e.: 100% ×[***]% × US$100,000,000 = US$[***])	 	Nil

	(b)
	If
as of the expiry of the second calendar quarter of Year X cumulative Net Sales for Year X exceed the First Threshold but do not exceed one billion US dollars (US$1,000,000,000)
(the "Second Threshold"), all royalties payable for such calendar quarter shall be calculated and paid as follows: (A) to DRC, the Royalty
Interest, which shall equal (I) one hundred per cent (100%) of royalties payable on cumulative Net Sales for Year X at or below the First Threshold plus (II) fifty per cent (50%) of
royalties payable on cumulative Net Sales for Year X above the First Threshold less (III) the First DRC Payment (collectively, the "Second DRC
Payment"); and (B) to ISIS, the ISIS Royalty Interest, which shall equal fifty per cent (50%) of royalties payable on cumulative Net Sales for Year X above the First
Threshold (the "First ISIS Payment"). i.e.: 

	Cumulative Net Sales as of

Expiry of Second Calendar

Quarter of Year X
	 	Royalty Interest/

Second DRC Payment
	 	ISIS Royalty Interest/

First ISIS Payment

	US$600,000,000	 	(I) 100% of all royalties payable on cumulative Net Sales for Year X at or below the First Threshold

plus

(II) 50% of all royalties payable on cumulative Net Sales for Year X above the First Threshold but at or below the Second Threshold

less

(III) the First DRC Payment

(i.e.: (100% ×[***]% × US$500,000,000) + [50% ×[***]% × (US$600,000,000 – US$500,000,001)] – US$[***] = US$[***])	 	50% of all royalties payable on cumulative Net Sales for Year X above the First Threshold

(i.e.: 50% ×[***]% ×(US$600,000,000 – US$500,000,001) = US$[***])

	(c)
	If
as of the expiry of the third calendar quarter of Year X cumulative Net Sales for Year X exceed the Second Threshold, all royalties payable for such calendar quarter shall be
calculated and paid as follows: (A) to DRC, the Royalty Interest, which shall equal (I) one 

31

 

hundred
per cent (100%) of royalties payable on cumulative Net Sales for Year X at or below the First Threshold plus (II) fifty per cent (50%) of royalties payable on cumulative Net Sales for
Year X above the First Threshold but at or below the Second Threshold plus (III) ten cent (10%) of all royalties payable on cumulative Net Sales for Year X above the Second Threshold less
(IV) the total of the First DRC Payment and the Second DRC Payment; and (B) to ISIS, the ISIS Royalty Interest, which shall equal (i) fifty per cent (50%) of all royalties payable
on cumulative Net Sales for Year X above the First Threshold but at or below the Second Threshold plus (ii) ninety per cent (90%) of all royalties payable on cumulative Net Sales for Year X
above the Second Threshold less (iii) the First ISIS Payment. i.e.: 

	Cumulative Net Sales as of

Expiry of Third Calendar

Quarter of Year X
	 	Royalty Interest
	 	ISIS Royalty Interest

	US$1,100,000,000	 	(I) 100% of all royalties payable on cumulative Net Sales for Year X at or below the First Threshold

plus

(II) 50% of all royalties payable on cumulative Net Sales for Year X above the First Threshold but at or below the Second Threshold

plus

(III) 10% of all royalties payable on cumulative Net Sales for Year X above the Second Threshold

less

(IV) the total of the First DRC Payment and the Second DRC Payment

(i.e.: (100% × [***]% × US$500,000,000) + [50% × [***]% × (US$1,000,000,000 – US$500,000,001)] + [10% × [***]% × (US$1,100,000,000 – US$1,000,000,001)] – (US$[***] + US$[***] = US$[***])	 	(i) 50% of all royalties payable on cumulative Net Sales for Year X above the First Threshold but at or below the Second Threshold

plus

(ii) 90% of all royalties payable on cumulative Net Sales for Year X above the Second Threshold

less

(iii) the First ISIS Payment

(i.e.: [50% × [***]% × (US$1,000,000,000 – US$500,000,001)] + [90% × [***]% × (US$1,100,000,000 – US$1,000,000,001)] – US$[***] = US$[***])

32

 
 
 

SCHEDULE "E"
  PATENTS    
    

[***] 

33

 
 
 

SCHEDULE "F"    
    

EXAMPLE TERMINATION EVENT RE-CONVEYANCE CALCULATION 

Assuming
that (i) DRC has re-conveyed to ISIS the Assigned Rights as they relate to the EU (as a result of the occurrence of a Special Event of Default) (the
"EU Re-conveyance"); (ii) in connection with the EU Re-conveyance it is determined that the EU Percentage equals 42%;
(iii) a Termination Event occurs following the EU Re-conveyance and prior to the Third Payment Date and (iv) as a result of a dispute DRC is not required to pay the third
installment or any Damages on account thereof, then the portion of the Assigned Rights that are to be re-conveyed by DRC to ISIS would be calculated based on the following: 

	(a)
	the
Assigned Rights relate to the US only;

	(b)
	the
Purchase Price for such Assigned Rights would equal US$13,920,000 (i.e. 58% of US24,000,000);

	(c)
	DRC
would have paid $[***] for such Assigned Rights (i.e. $13,920,000 less US$[***] (i.e. 58% of $[***]));

	(d)
	the
corresponding portion of the Assigned Rights that DRC would have purchased would be equal to [***]% (i.e. $[***]divided by
$13,920,000); and

	(e)
	the
outstanding Purchase Price amount payable on the Third Payment Date for such Assigned Rights would be $[***] (i.e. 58% of $[***]). 

In
this example, as at the Termination Event, DRC would therefore be required to re-convey [***]% (i.e. 100% less [***]%) of the Assigned
Rights that DRC held as at such date to ISIS. 

34

QuickLinks

AGREEMENT FOR SALE AND ASSIGNMENT OF RIGHTS

ARTICLE 1 ASSIGNMENT AND SALE

ARTICLE 2 REPRESENTATIONS AND WARRANTIES

ARTICLE 3 COVENANTS

ARTICLE 4 CLOSING; DELIVERIES ON CLOSING

ARTICLE 5.A SPECIAL EVENTS OF DEFAULT

ARTICLE 5 TERM AND TERMINATION

ARTICLE 6 MUTUAL INDEMNITY

ARTICLE 7 MISCELLANEOUS

SCHEDULE "A" DEFINITIONS

SCHEDULE "B" CALCULATION OF ROYALTY INTEREST AND ISIS ROYALTY INTEREST

SCHEDULE "E" PATENTS

SCHEDULE "F"

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]